Family, Science and Art of Jose F. Caro M.D.

Subtitle

Medicine and Science  CV. Please see also Art Milestones

                                                                                                                    

Curriculum Vitae


Jose F. Caro, M.D.


GENERAL INFORMATION

Home Address:             5947 McKinges Circle

                                         Carmel, IN 46033 

                 

Email:                             [email protected]  

webs:                              www.josefcaro.com

                                        

 Birthplace:                 Granada, Spain

Citizenship:         USA

Marital Status: Married with Marice E. Caro for 40 years

Children:                Maricelina, Rodolfo, Marina and Rafael

Grand Children:         Olivia, Elise, Bridget, Julia and Julian

 

Summary

 

Jose F. Caro began a new career in art in 2008. He went back to college to pursue a degree in fine art and is having his pastel paintings peer reviewed by his colleagues. Before this transformation he was the Vice President of Endocrine Research and Clinical Investigation and Global Diabetes Care at Eli Lilly & Comp for 12 years. Prior to joining Lilly he was the Magee Professor of Medicine and Chairman of the Department at Jefferson Medical College for 5 years and the Chief of Endocrinology and Director of the University Diabetes Center at East Carolina University for 10 years.


 Dr. Caro received his M.D. degree with honors in 1973 from the School of Medicine in Madrid, Spain and Montevideo, Uruguay. He completed residency and fellowship training at Jefferson Medical College and at the University of Rochester. He is Board Certified in Internal Medicine and Endocrinology and Metabolism.


Dr. Caro was a member of various professional and honorary societies, including the American Society for Clinical Investigation (Young Turk) and the Association of American Physicians (Old Turk). He was the recipient of the Medal of Honor and is an honorary member of the Real Academy of Medicine of Granada, Spain. He is the Honorary Director of the Peking Diabetes Center and Honorary Professor of the Peking University Health Science Center in China.Dr. 


He has authored about 200 papers, book chapters and books and he was recently listed as the third most highly cited investigator in the world in the field of Obesity Research by ISI. He served as Editor and Editorial Board member of several journals and has lectured around the world. Dr. Caro has served as a member and Chairman of several study sections at the NIH and more recently as a member of the NIDDK Advisory Council to the President.


He lives in Carmel IN with Marice, his spouse for 42 years. His main artistic inspiration is his family...his four children and five grandchildren.

 


MEDICAL EDUCATION

1967 - 1973 School of Medicine, Universidad Autonomy, Madrid, Spain and School of Medicine, Universidad de la Republica, Montevideo, Uruguay 

POSTGRADUATE TRAINING

1974 - 1977 Residency in Internal Medicine, Thomas Jefferson University Hospital of Thomas Jefferson University, Philadelphia, Pennsylvania

1977 - 1978 Fellowship in Internal Medicine, Thomas Jefferson University Hospital of Thomas Jefferson University, Philadelphia, Pennsylvania

1978 - 1981 Fellowship in Endocrinology and Metabolism, Strong Memorial Hospital, University of Rochester School of Medicine and Dentistry, Rochester, New York

CERTIFICATIONS

1979 Board Certification in Internal Medicine, American Board of Internal Medicine

1984 Board Certification in Endocrinology and Metabolism, American Board of Internal Medicine

APPOINTMENTS

1981 - 1983  Assistant Professor of Medicine, Endocrinology and Metabolism, Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania

1983 - 1986  Associate Professor of Medicine, Section Head of Endocrinology and Metabolism, East Carolina University School of Medicine, Greenville, North Carolina

1986 - 1991   Professor of Medicine, Section Head of Endocrinology and Metabolism and Director of the University Diabetes Center, East Carolina University School of Medicine, Greenville, North Carolina

                 

                                  The Division of Endocrinology and Metabolism was founded. Six faculties were recruited and mentored and all became funded by the NIH. A comprehensive Fellowship Program was approved. The ECU Diabetes and Obesity Center was established. Dr. J. F. Caro became Program Director of the “ECU Diabetes Program Project”, the largest NIH award in the history of the University. Basic research discoveries were made such as mechanism(s) of IRTK defects in liver, muscle and liver from humans with diabetes and clinical research observations were made such as that the gastric bypass surgery prevent diabetes by 40 folds in people with pre-diabetes and reverse diabetes in more than 80 percent of patients for more than 10 years.

1991 - 1996   Magee Professor of Medicine and Chairman of the Department, Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania

                                The Department of Medicine tripled its NIH funding and moved from the middle third to the upper third of NIH ranking. The residency program became the largest in the State with most house staff electing a career on primary care. Out patient encounters tripled and hospital’s patient duration of hospitalization decreased by half. The budget of the Department continued generating overage for program development. All this was achieved without a significant increase in FTEs. This is what our Dean called “productivity without expansion”

1996 - 2008    Vice President, Endocrine Research and Clinical Investigation and Vice President of Global Diabetes Care. Lilly Research Laboratories, Eli Lilly & Comp, Lilly Corporate Center, Indianapolis, IN

                                 The focus was on drug discovery from hypothesis generation in the laboratory to prove of concept in phase 2 clinical trials. The effort involved a heavily matrix organization with chemistry, toxicology, ADME, biology, clinical pharmacology, marketing, business, etc. More than 40 compounds were discovered that fulfilled all FDA requirements to enter clinical trials. The endocrine portfolio transformed from only Insulin to a more complete portfolio with several INDs and NDAs still in clinical trials from this decade’s drug discovery pipeline.

1996 - 2008      Professor of Medicine, Indiana University School of Medicine,  Indianapolis, IN

2005 - Present      Distinguished Professor of Medicine, Emeritus, East Carolina University School of Medicine, Greenville, NC

2007 – Present    Co-Founder, Chief Scientific Officer Emeritus and Honorary Member of the Executive Committee of Peers for Progress. AAFP, University of North Carolina, Chapel Hill, NC

2012-Present                 President and Founder, JFC Solutions LLC


AWARDS AND RESEARCH GRANTS ( direct cost only)

1979 - 1981 Juvenile Diabetes Foundation Fellowship Award (P.I.) ($75,000)

1981 - 1983 American Diabetes Association Wayne Newton Research Grant (P.I.) ($68,750)

1981 - 1982 Small Grant Award PHS Biomedical Research Support Grant 5 S07 RR0514, Jefferson Medical College (P.I.) ($12,500)

1981 - 1982 Department of Medicine Research Grant, Jefferson Medical College (P.I.) ($12,500)

1981 - 1983 Juvenile Diabetes Foundation Research Grant (P.I.) ($110,000)

1982 - 1983 Research Grant, Upjohn Company (P.I.) ($31,250)

1982 - 1985          New Investigator Research Award 1 R23AM 30558, National Institutes of Health (PI) ($176,500)

1984 - 1985 Research Grant, 5-81011 Years Laboratories (P.I.) ($43,750)

1985 - 1987 Research Grant, Upjohn Company (P.I.) ($50,000)

1985 - 1988 Research Grant, R01-AM 32585 National Institutes of Health (P.I.) ($297,000)

1986 - 1990        Research Grant, R01-DK 38066 National Institutes of Health (P.I.) (This grant was funded but was inactivated because of overlap with Program Project DK 36296

1987 - 1988 Sponsor of Fogerty Fellowship Award from the National Institutes of Health (IF05TW04048) to Dr. Ivan Contreras

1987 - 1992 ECU Diabetes Program Project, P01-DK 36296 National Institutes of Health (Program Director) $2,550,000)

1987 - 1992 Research Grant, Eli Lilly Company (P.I.) ($375,000)

1988 - 1989 Research Grant, Glaxo Pharmaceutical Company (P.I.) ($62,500)

1988 - 1989 Research Grant, R03-DK 41191-1 National Institutes of Health (P.I.) ($41,250)

1988 - 1989 Research Grant, Pfizer Pharmaceutical Company (P.I.) ($30,000)

  

1989 - 1992         Sponsor of Fellowship Award from the National Institutes of Health (IF32DK08477) to Dr. Jacob Friedman

1990 - 1991 Research Grant, Park Davis Pharmaceutical Company (P.I.) ($100,000)

1990                 Small Grant Award: Roaring Visiting Professorship Program in Diabetes Management  ($6,250)

1990 Research Grant, 1R03-DK 2924 National Institutes of Health (P.I.) ($41,250)

1990 - 1992 Research Grant, Amylin Pharmaceutical Company (P.I.) ($100,000)

1991 - 1993 Sponsor of Fellowship Award to Dr. Bartolome Burguera from the Juvenile Diabetes Foundation

1991 - 1992 Research Grant, Hoechst-Roussel Pharmaceuticals, Inc. (P.I.) ($62,500)

1992 - 1994 Sponsor of Fellowship Award to Dr. Robert Considine from the National Institutes of Health (IF32DK08888)

1993 - 1994 Research Grant, Eli Lilly Company (P.I.) ($96,015)

1993 - 1994 Research Grant, Eli Lilly Company  (Co-PI) ($65,235)

1993 - 1995 Research Grant, Amylin Pharmaceutical, Inc. (P.I.) ($37,676)

1994 - 1995 Research Grant, Miles Laboratories (P.I.) ($153,125)

1994 - 1995 Research Grant, Pfizer Pharmaceuticals (Co-Invest.) ($37,500)

1994 - 1996 Research Grant, CI-991, Park Davis Pharmaceuticals (Co-Invest.) ($47,000)

1992 - 1997 Research Grant, R01-DK 44950 National Institutes of Health (P.I)  ($1,900,000)  

1994 - 2002 Research Grant, UO1-DK48468, National Institutes of Health (P.I.) ($3,422,165)


SPECIAL RESEARCH GRANTS

2006-2012                  Bringing Research In Diabetes Through  Environment and Systems(BRIDGES). See   Press Release Cape Town, South Africa, 5 December 2006 [email protected]  Dr. Caro identified the need of translational research in diabetes at the global level. He wrote a Grant to the Lilly Foundation and provided support to the International Diabetes Federation.  ($10,000,000)

2007-2012            Peers for Progress. See Press Release Leak wood, KS, USA, June 20, 2007,www.lilly.com/product/acceess/foundation, Peersforprogress.org

                                 Dr. Caro identified the need of new methods for patient education in diabetes. He wrote a Grant to the Lilly Foundation and provided support to the American Academy of Family Physicians Foundation. Peers for progress will identify and train lay volunteers who have diabetes and empower them to assist other people with diabetes. The goal is to educate one percent of the people with diabetes or two million diabetes to became mentors around the world. The concept was validated at a World Health Organization consultation, 5-7 November 2007 in Geneva. ($15,000,000)

HONORS AND NAMED LECTURESHIPS

1986-1992 Recipient of the “ Pearl Lecturer” every year while in the Faculty (Senior Medical Students' Teaching Award). East Carolina University School of Medicine, Greenville, NC

1988 -2012 Member of the American Society of Clinical Investigators (Young Turk)

1991 Outstanding Investigator Award. Department of Medicine Fifth Annual Research Day, East Carolina University School of Medicine, Greenville, NC, 1991.

1992 Karl Paschkis Lecturer, "NIDDM: Lessons from the Laboratory."  The Philadelphia Endocrine Society, Philadelphia, Pennsylvania, 1992.

1993 Bernardo A. Houssay Lecturer, "Insulin Resistance in Type II Diabetes", International Diabetes Foundation and The Costa Rican Association of Endocrinology, San Jose, Costa Rica, 1993.

1996 Mithoffer Lecturer, "Leptin:  The Tale of an Obesity Gene", Medical University of South Carolina, Charleston, SC, 1996. 

1996 Alexander Marble Lecturer, “Obesity: A syndrome of Leptin Resistance”. Joslin Diabetes Center.  Harvard Medical School. Boston, Massachusetts, 1996.

1997 Banting and Best Lecturer: “Discovery of Leptin”. University of Toronto.  Canada Diabetes Association.  Toronto, Canada, 1997

1998 Eugene Furth Lecturer “On the trail to cure Diabetes”  East Carolina University School of Medicine, Greenville, North Carolina,  1998

1998 A.M. Cohen Memorial Lecturer: “On the Trail to Cure Diabetes”.  VII International Symposium on Insulin Receptors and Insulin Action: Molecular and Clinical Aspects.  Jerusalem, Israel,  1998

1998 Recipient of the Medal of Honor and Honorary Membership to the Real Academy of Medicine of Granada.  Granada, Spain, 1998

1991 - 2001 The third most highly cited investigators in the field of Obesity Research by the Institute for Scientific Information (I.S.I).

2000 - 2012 Member of the Association of American Physicians (Old Turk)

2004 - present Honorary Director of the Peking Diabetes Center and Honorary Professor of the Peking University Health Science Center.  Peking, China.

2005 The Leslie Nicholas Lecture “The scientific Basis of New Therapies for Obesity”. The College of Physicians of Philadelphia, PA

  

EDITORIAL ACTIVITIES

1988 - 1996 Associate Editor, Advances in Diabetologia

1991 - 1997 Associate Editor, Diabetes Care

1991 - 2002 Editorial Board, Journal of Clinical Endocrinology and Metabolism

1992 - 2002 Section Editor, Obesity Research, North American Association for the Study of Obesity

1994 - 1999 Associate Editor, Medicina y Cultura

1985 - 2008 Associate Editor, Metabolism Clinical and Experimental

2001 -2005 Section Editor, Nutrition and Obesity, Endotext.com

2004 - 2006 Co-Editor, The Metabolic Syndrome at the Beginning of the XXI Century:  A Genetic and Molecular Approach  

2005 - 2008           Editorial Board, Journal of Clinical Endocrinology and Metabolism

2005 – 2008   International Editorial Board, Obesity and Metabolism

CONSULTANT ACTIVITIES TO NIH

1985 - 1989 Member, Metabolism Study Section, National Institutes of Arthritis, Diabetes and Kidney Diseases.  National Institutes of Health

1989 Special Reviewer, Study Section for Small Business Innovation Research, Pharmacology Panel, National Institutes of Health

1989 Member, Site Visit Team, General Clinical Research Center Committee.  National Institutes of Health

1989 Member, Site Visit Team to review a NIH General Clinical Research Center

1990 Member, Clinical Sciences Study Section Site Visit.  National Institutes of Health

1991 Member, NIH Site Visit Team, General Clinical Research Center

1992 Member, Special Review Committee, National Institute of General Medical Sciences, NIH

1992 Member, External Advisory Committee, Sims' Obesity and Nutrition Research Center, NIDDK and NICHD

1992 Member, NIDDK Special Grant Review Committee

1992 Chairman, Diabetes Endocrinology Research Center Study Section, NIH, Bethesda, Maryland

1992 Member, Site Visit Team, General Clinical Research Center, National Institute of Health

1993 Chairman, Ad Hoc Review Group SSS-L Clinical Sciences Review Section, National Institute of Health.

1994 Member, Behavioral and Neurosciences Special Emphasis Panel, NIH

1995 Member, Ad Hoc Review Committee, Diabetes Research and Training Centers, National Institute of Health

1998     Member, Congressionally Mandated Diabetes Research Working Group and Chairman of the Industry/Academia Subgroup, NationalInstitute of Health (NIH).

1996 - 2000  Member, Subcommittee B of the Diabetes and Digestive and Kidney Diseases Special Grants Review Committee, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH

2000 - 2004  Member of the National Institute of Digestives and Diabetes and Kidney Diseases Advisory Council, NIH and Chairman of the Concurrence Grant Awards Approval Committee of the NIDDK Advisory Council, NIH

2000 – 2004  Member of the Disease Prevention and Management Working Group, Advisory Council of the National Institute of Diabetes and Digestive and Kidney Diseases, NIH

2000 – 2004     Member of the Advisory Council Operating Procedures Working Group, NIDDK Advisory Council, NIH


CONSULTANT ACTIVITIES TO THE AMERICAN DIABETES ASSOCIATION

1984 - 1985 Chairman, Patient Education Committee, American Diabetes Association, North Carolina

1984 - 1985 President, American Diabetes Association, Pitt County Chapter, North Carolina

1985 - 1986 Chairman, Patient Education Committee, American Diabetes Association, North Carolina Affiliate

1988 - 1991 Member, Professional Education Committee, American Diabetes Association

1989-1991 Member, Committee on Scientific and Medical Profession.  American Diabetes Association

1992 Member, Grant Review Panel, Studies on Genetics in NIDDM, American Diabetes Association, New York, NY.  

1989-1991 Master Faculty, Clinical Education Program, "Managing Diabetes in the 1990's," American Diabetes Association.

1990 - 1991 President Elect, American Diabetes Association, North Carolina Affiliate

1991 - 1992 President, American Diabetes Association, North Carolina Affiliate

1992 - 1996 Member, Board of Directors, American Diabetes Association, Pennsylvania Affiliate

1992 - 1996 Member, Professional Education Committee, American Diabetes Association, Pennsylvania Affiliate

1993 Panel member, Consensus Development Conference on the Treatment of Hypertension in Diabetes, American Diabetes Association

1993 - 1996 Member of the Academic Steering Committee, Professional Diabetes Academy

1994 - 1996 Chairman, Scientific and Medical Meetings Oversight Committee of the American Diabetes Association

1994 - 1996 Member, Professional Section Advisory Panel of the American Diabetes Association

MEDICAL SCHOOL COMMITTEES

1985 - 1986 Member, Policy and Review Committee on Human Research, East Carolina University

1985 - 1986 Member, House Staff Evaluation Committee, East Carolina University

1985 - 1991 Member, Human Organ Transplant Committee, East Carolina University

1985 - 1991 Member, Department of Medicine Research Advisory Committee,
East Carolina University

1986 - 1987 Member, Radiation Safety Committee, East Carolina University

1986 - 1987 Member, Institutional Review Committee, Pitt County Memorial Hospital

1987 - 1988 Member, Dean's Search Committee (Elected by the Faculty), East Carolina University

1987 - 1991 Member, Jacob Furth Prize Committee, East Carolina University

1989 - 1990 Chairman, Ad Hoc Committee, Clinical Research Center, School of Medicine, East Carolina University

1989-1990 Member, Ad Hoc Committee, Medical School Core Laboratory Facilities.  School of Medicine, East Carolina University

1991 Member, Search Committee for Chairman of the Department of Medicine (Elected by the faculty), East Carolina University

1995 - 1996 Member, University Advisory Committee on International Affairs, Thomas Jefferson University

1995 - 1996 Secretary, Jefferson Faculty Foundation Executive Committee, Jefferson Medical College

1995 Member, Jefferson Faculty Foundation Finance Committee, Jefferson Medical College

OTHER CONSULTANT/COMMITTEE WORK

1986-1996 Ad Hoc Reviewer, Research Grants Program.  Veterans Administration, Washington, DC

1988 - 1992 Member of the Medical Science Review Committee, Juvenile Diabetes Foundation International

1989-1999 Ad Hoc Reviewer, National Science Foundation.  Washington, DC

1989-1991 Member, Board of Medical Advisors.  Amylin Corporation, San Diego, CA

1992 - 1996 Member, Board of Trustees, Methodist Hospital, Philadelphia, PA

1992 - 1996 Member, Board of Trustees, Magee Rehabilitation Hospital, Philadelphia, PA

1992 - 1996 Member, Board of Directors, Philadelphia Endocrine Society

1993 - 1996 Member, Boston Obesity/Nutrition Research Center Scientific Advisory Group

1993 - 1994 Member, Education Committee, Professional Diabetes Academy

1994 - 1996 Member, Academic Advisory Committee of the Pfizer Visiting Professorship Program in Diabetes Management

1994 Member, Committee on Faculty and Researchers, Interamerican College of Physicians and Surgeons

2001 - 2005 Member, JDRF Management Advisory Board

2004 Member, American Obesity Association Advisory Board

PROFESSIONAL SOCIETIES/MEMBERSHIPS

1976 -2010 Member, American Society of Internal Medicine

1977 -2010 Member, American College of Physicians

1979 - 2010             Member, American Federation for Clinical Research

1980 - 2010 Member, American Diabetes Association

1980 - 2010 Member, Endocrine Society

1984 - 2010 Member, American Association for the Advancement of Science

1984 - 2010 Member, American Medical Association

1984 - 1992 North Carolina Medical Society

1988 - 2010 Member, American Society for Clinical Investigation (Young Turk)

1991 - 2010 Member, Sigma Xi, The Scientific Research Society

1992 - 1997 Pennsylvania Medical Society

1992 - 1997 Philadelphia County Medical Society

1992 - 1997 College of Physicians of Philadelphia

1992 - 2010 Charter Member, American Association of Clinical Endocrinologists

1993 - 2010 Fellow, American College of Physicians

1993 - 2010             Member, North American Association for the Study of Obesity

1993 - 2010 Member, Professional Diabetes Association

1995 - 2010 Member, Society of Ibero Latin American Medical Professionals

1996 - 1997 Member, American Society for Clinical Pharmacology and Therapeutics

2000 - 2010 Member, Association of American Physicians (Old Turk)

SPECIAL POST GRADUATE EDUCATION

1992 Program for Chiefs of Clinical Services, Harvard School of Public Health

1993 Program for Executives in Managed Care, Harvard School of Public Health

VISITING PROFESSORSHIPS AND SPECIAL LECTURES

Invited Speaker. "Mechanism of Insulin Resistance in Uremia." University of Pennsylvania. Philadelphia, PA, 1981

Invited Speaker. "Insulin Binding and Processing in Isolated Rat Hepatocytes." University of Virginia. Charlottesville, VA, 1981

Invited Speaker. "Insulin Resistance in Uremia." University of South Florida. Tampa, FL, 1982

Invited Speaker. "Insulin Resistance in Uremia." Duke University School of Medicine. Durham, NC, 1982

Program Chairman. "The Diagnoses and Treatment of Type II Diabetes." American Diabetes Association and East Carolina University School of Medicine. Greenville, NC, 1984

Invited Speaker. "Management of Type II Diabetes." At the "First Congress in Washington, DC of the Interamerican College of Physicians and Surgeons." Washington, DC, 1984

Invited Speaker. "Mechanism of Insulin Action" and "Hyperlipidemia in Diabetes." The Third Annual Scientific Panel and the University of Zulia. Maracaibo, Venezuela, 1985

Invited Speaker. "Gastric Bypass: A Human Model to Study Diabetes." Duke University School of Medicine. Durham, NC, 1985

Visiting Professor. "Mechanism of Insulin Resistance in the Human Liver from Patients with NIDDM." University of Rochester School of Medicine and Dentistry. Rochester, NY, 1986

Moderator. "Learn by Sharing." Patient Education Program of the American Diabetes Association, North Carolina Affiliate. Raleigh, NC, 1985

Invited Speaker. "Diabetic Emergencies" and "Office Management of Type II Diabetes." 14th Annual Beach Workshop. Myrtle Beach, SC, 1986

Invited Speaker. "Insulin Receptor Kinase Activity in Human Liver, Muscle, and Adipose Tissue." Lilly Research Laboratories. Indianapolis, IN, 1986

Visiting Professor. "ECU Diabetes Program Project." Diabetes Branch of the National Institutes of Health, Bethesda, MD, 1986

Visiting Professor. "Mechanism of Insulin Resistance in Type II Diabetes." Geriatric Research Center, Johns Hopkins University School of Medicine. Baltimore, MD, 1986

Visiting Professor. "The Mechanism of Insulin Resistance in Type II Diabetes." Department of Pathology, University Complutense School of Medicine. Madrid, Spain, 1986

Invited Speaker. "The Human Endocrine System: A Brief Review." At the Fourth Annual Biotechnology Symposium." East Carolina University School of Medicine. Greenville, NC, 1986

Visiting Professor. "Insulin Receptor Kinase in Important Target Tissues for Insulin in Type II Diabetes Mellitus." Department of Medicine, University of Rochester School of Medicine and Dentistry. Rochester, NY, 1987

Invited Speaker. "The Insulin Receptor and Liver, Skeletal Muscle, and Adipose Tissue from Humans with and without Type II Diabetes." Lilly Diabetes Care International Symposium.  Indianapolis, IN, 1987

Invited Speaker. "Mechanisms of Insulin Resistance in Type II Diabetes." At the "National Institutes of Health Centennial, Nurturing Creative Research Genius for Biomedicine." Duke University School of Medicine. Durham, NC, 1987

Symposium Chairman. "Diabetes Mellitus: Management in Pregnancy and Childhood." American Diabetes Association and East Carolina University School of Medicine. Greenville, NC, 1987

Invited Speaker. "Type II Diabetes Mellitus: Treatment and Complications." The XI Interamerican Medical Congress of the Spanish-American Medical Society. New York, NY, 1987

Visiting Professor. "Mechanisms of Insulin Resistance in Type II Diabetes." University of Virginia Diabetes Center, Charlottesville, VA, 1987

Visiting Professor. "Role of Insulin Receptor Tyrosine Kinase in Insulin Resistance." Glaxo Research Laboratory. Research Triangle Park, NC, 1987

Invited Speaker. "Advances in the Treatment of Type II Diabetes." At the XII Annual Conference of the North Carolina Academy of Physicians." Wrightsville, NC, 1988

Invited Speaker. "Carbohydrate Metabolism in Diabetes." At the "IX Annual Congress of the Spanish Society of Diabetes." Barcelona, Spain, 1988

Invited Speaker. "Current Views of Etiology of Type II Diabetes: Are We Getting There?" At "Diabetes Update 1988." American Diabetes Association and East Carolina University School of Medicine. Southern Pines, NC, 1988

Invited Speaker. "The Insulin Receptor in Obesity and NIDDM: A New Target for Clinical and Basic Research." At a symposium on the "Mechanism of Insulin Resistance in Type II Diabetes" 70th Annual Meeting of the Endocrine Society. New Orleans, LA, 1988

Visiting Professor and Clinical Scholar. Lilly task force on "Early Recognition and Prevention of Diabetes." Lilly Research Laboratories. Indianapolis, IN, 1988

Invited Speaker. "Diabetic Emergencies." North Carolina Family Physician's Annual Meeting. Wrightsville Beach, NC, 1988

Invited Speaker. "Diabetes." Geriatric Medicine Board Review. East Carolina University School of Medicine. Greenville, NC, 1988

Visiting Professor. "Mechanism of Insulin Resistance in Type II Diabetes." Veterans Administration Medical Center at Georgetown University. Washington, DC, 1988

Invited Speaker. "Insulin Receptor Kinase Alterations." At the "Action of Insulin and Related Growth Factors in Diabetes Mellitus." Celebrating Joslin's 90th Anniversary. Joslin Diabetes Center and Harvard Medical School. Boston, MA, 1988

Visiting Professor. "Mechanism of Insulin Resistance in Type II Diabetes." University of Illinois Chicago, IL, 1988

Visiting Professor. "Insulin Resistance." University of California, San Diego, CA, 1988

Invited Speaker. "Devastation of the Disease: Type II Diabetes." Third Hispanic Medical Congress. Washington, DC, 1988

Visiting Professor. "Mechanism of Insulin Resistance in Type II Diabetes" and "Chronic Complications of Diabetes." Diabetes Branch of the National Institutes of Health. Bethesda, MD, 1988

Visiting Professor. "Mechanism of Insulin Resistance in Type II Diabetes" and "Chronic Complications of Diabetes." University of Colorado Health Sciences Center. Denver, Colorado, 1988

Visiting Professor. "Mechanism of Insulin Resistance in Type II Diabetes." Diabetes Clinical Research Institute, Charlottesville, VA, 1989

Visiting Professor. "The Insulin Receptor: A New Target For Basic and Clinical Investigations." Research Seminar, Emory University, Atlanta, GA, 1989

Visiting Professor. "Mechanism of Insulin Resistance in Type II Diabetes." Diabetes Center of Eastern Virginia, Norfolk, VA, 1989

Invited Speaker. "Mechanism of Insulin Action." Inter-University Post-Graduate course on Molecular Mechanism of the Endocrine System, Fundacion Ramon Areces, Madrid, Spain, 1989

Keynote Speaker. "The Pathogenesis of Obesity" and "Meet the Professor: Problem Case Discussion." At Diabetes Mellitus - Challenges in the 1990's." American Diabetes Association, Hilton Head Island, SC, 1989

Invited Speaker. "Clinical and Physiological Correlates of Glucose Transport in Obesity and Diabetes" at "The Symposium in Frontiers in the Molecular and Cellular Biology and Glucose Transport." 49th Annual Meeting and Scientific Sessions, American Diabetes Association, 1989

Invited Speaker. "Insulin Resistance in Obesity: Towards a Molecular Approach." UCLA Symposium on Molecular and Cellular Biology, Keystone, Colorado, 1989

Keynote Speaker. "Advances in Diabetes Mellitus" at the Mexican Society of Nutrition and Endocrinology, Monterey, Mexico, 1989

Keynote Speaker. "Obesity and Insulin Resistance" and "Meet the Professor: Diabetes Mellitus and Hypertension" at the IV International Congress of Medicine, Victoria, Mexico, 1989

Invited Speaker. "Studies on the Mechanism of Insulin Resistance in Type II Diabetes." Merck, Sharp, & Dohme Co. Rahway, NJ, 1989

Invited Speaker. "The Insulin Receptor and Post Receptor in Liver in NIDDM: Effects of Sulfonylureas." Fourth International Conference on Diabetes. University of Virginia, Charlottesville, VA, 1989

Keynote Speaker. "Cellular Alterations in Liver, Muscle, and Adipose Tissues Responsible for Insulin Resistance in Diabetes." Meeting of the Diabetes Treatment Centers of American Foundation. 1989 Annual Physicians Conference. Palm Desert, CA, 1989

Invited Speaker. "Diabetes is a Serious Disease" 42nd Annual Scientific Assembly of the North Carolina Academy of Family Physicians. Greensboro, NC, 1990

Invited Speaker. "Cellular Alterations in Liver, Muscle, and Adipose Tissue Responsible for Insulin Resistance in NIDDM." Hershey Medical Center, Hershey, PA, 1990

Invited Speaker. "Alterations in Insulin Receptors and Glucose Transporters in Obese and Diabetic Humans," at the Satellite Meeting of the XI Amsterdam International Congress of Pharmacology, "Pathophysiology and Treatment of Diabetes Mellitus" Montpellier, France, 1990

Invited Speaker. "Altered Coupling of the Insulin Receptor with Gi Protein in the Liver from Patients with NIDDM" at the International Symposium on Obesity and Diabetes Mellitus, Nagoya, Japan, 1990

Invited Speaker. "Insulin Action in Adipose Tissue and Muscle in Human Obesity and Diabetes" at the 6th International Congress on Obesity, Kobe, Japan, 1990

Invited Speaker, "Diagnosis and Treatment of Diabetes Mellitus" and "Insulin Resistance in Obesity and Diabetes Mellitus" at the LII National Medical Congress, San Jose, Costa Rica, 1990

Invited Speaker, "Post-Receptor Defect in Type II Diabetes" American Diabetes Association, Minneapolis Affiliate, Minneapolis, MN, 1990

Invited Speaker, "G-Proteins in Diabetes" at the Mayo Clinic, Rochester, NY, 1990

Invited Speaker, "Overview of Alterations in Insulin Action in Human Diabetes" at the UCLA Symposium on Molecular and Cellular Biology, Park City, Utah, 1991

Invited Speaker, "Mechanism of Insulin Resistance in NIDDM." Miles Laboratories, West Haven, Connecticut, 1991

Invited Speaker, "Mechanisms and Management of Type II Diabetes." New Mexico Metabolism Symposium 1991. Taos, New Mexico, 1991

Invited Speaker, "Mechanism of Insulin Resistance in Type II Diabetes. "Baylor College of Medicine, Houston, Texas, 1991

Invited Speaker, "Diabetes Mellitus Prevention in the High Risk Patient," at the "Current Advances in Nutritional Medicine and Disease Prevention." Harvard Medical School, Boston, MA, 1991

Invited Speaker, "NIDDM: Insulin Resistance vs. Insulin Secretion." NJ Affiliate of the ADA, Jamesburg, NJ, 1991

Keynote Speaker, "Diabetes in the 90's." American Diabetes Association, NC Affiliate, Raleigh, NC, 1991

Invited Speaker, "Insulin Resistance in NIDDM." University of Chicago, Chicago, IL, 1991

Invited Speaker, "Carbohydrate Metabolism in Obesity and Diabetes." Nutrition and Diabetes Mellitus: Focus for the 1990's. A Satellite Symposium of the 14th IDF Congress. Baltimore, MD, 1991

Invited Speaker, "Physiology of Insulin Action in Muscle." 14th International Diabetes Federation Congress, Washington, DC, 1991

Invited Speaker, "Mechanism of Insulin Action." Satellite Symposium, 14th IDF Congress, Airily, VA, 1991

Visiting Professor, "Cellular Alterations in Liver, Skeletal Muscle, and Adipose Tissue Responsible for Insulin Resistance in Obesity and Type II Diabetes." Symposium organized by the USSR Academy of Medical Sciences and the USSR Ministry of Health, Moscow, Russia, 1991

Invited Speaker, "The IGF-1 Receptor in NIDDM: A Pathway to Bypass Insulin Resistance?" 39th Annual Clinical Society Scientific Meeting of the American Diabetes Association, New York Downstate Affiliate, New York City, 1991

Invited Speaker, "Mechanism of Insulin Resistance in Obesity." Workshop sponsored by the National Diabetes Advisory Board, National Institutes of Health, Arlington, VA, 1991

Invited Speaker, "Syndrome X."  11th Annual Day of Diabetes, American Diabetes Association, Columbus, Georgia, 1992

Invited Speaker, "Insulin Resistance in Obesity and Non-Insulin Dependent Diabetes:  Cause or Effect."  Western Metabolism Club, Carmel, California, 1992

Visiting Professor,  "Fat 1992", Grand Rounds, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, 1992

Invited Speaker, "Alteraciones a nivel de receptor y post receptor en la obesidad," XXV Congreso Nacional de la Sociedad Española de Ciencias Fisiológicas, Cordoba, Spain, 1992

Keynote Speaker, "Aspectos moleculares de la diabetes mellitus no insulinodependiente", VIII Congreso Asociación Latinoamericana de Diabetes, Buenos Aires, Argentina, 1992

Simposium Speaker, "Resistencia insulinica: su rol en diversos síndromes," VII Congreso Asociación Latinoamericana de Diabetes, Buenos Aires, Argentina, 1992

Visiting Professor, "Weight Loss:  Is it a Miracle?", Cooper Hospital/University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Camden, New Jersey, 1992

Visiting Professor, "Insulin Resistance in Type II Diabetes", University of Pittsburgh, Pittsburgh, Pennsylvania, 1992

Visiting Professor, "Pharmacological methods to bypass insulin resistance", Department of Biochemistry, University of Medicine and Dentistry of New Jersey/School of Osteopathic Medicine, Stratford, New Jersey, 1992

Invited Speaker, "Insulin Resistance in Type II Diabetes", International Diabetes Federation Congress and the Dominican Republic Association of Endocrinology, Santo Domingo, Dominican Republic, 1993

Visiting Professor, "Insulin Resistance", State University of New York Health Science Center at Brooklyn, Brooklyn, New York, 1993

Visiting Professor, "Insulin Resistance:  A target for the Clinical and Basic Investigator", The Milton S. Hershey Medical Center of the Pennsylvania State University, Hershey, Pennsylvania, 1993

Invited Speaker, "Beyond the Basics:  Neuropathy", the 13th Annual Diabetes Update '93 - American Diabetes Association, Philadelphia, Pennsylvania, 1993

Invited Speaker, "Obesity:  A Disease of the Adipose Tissue", National Institutes of Health, Bethesda, Maryland, 1993

Invited Speaker, "The ABCs of Thyroid Disease", Eastern Shore Medical Symposium, Rehoboth Beach, Delaware, 1993 

Visiting Professor, "Gene Therapy for Insulin Resistance", Department of Biochemistry, School of Medicine, Universidad Complutense, Madrid, Spain, 1993

Keynote Speaker, "Diabetes in Latinos" 8th Hispanic Medical Congress.  The Interamerican College of Physicians and Surgeons, San Juan, Puerto Rico, 1993 

Invited Speaker, "The Translation of the DCCT to the Care of Patients with Type II Diabetes Mellitus" The Opening Symposium of the Joslin Center for Diabetes at Jefferson Medical College and Wills Eye Hospital, Philadelphia, 1994

Invited Speaker, "Weight Loss in Severely Obese Subjects Prevents Type II Diabetes"  International Symposium sponsored by the Chinese Nutrition Society and Shanghai Nutrition Society.  Beijing, China, 1994

Invited Speaker, "Thyroid Nodules" Diabetes-Endocrine Symposium, Medical College of Pennsylvania, Philadelphia, Pennsylvania, 1994

Leadership Workshop:  "Therapeutic Choices in NIDDM” 54th Annual Meeting, American Diabetes Association, New Orleans, 1994

Invited Speaker, "Morbid Obesity and Diabetes" 7th International Congress of Obesity Satellite Symposium on Surgical Treatment of Obesity, Montreal, Quebec, Canada, 1994

Keynote Speaker, "Insulin Resistance from the laboratory to the bedside", XVI Internal Medicine Chilean Congress, Santiago, Chile, 1994

Symposium Speaker, "Current and future treatment of Diabetes Mellitus", XVI Internal Medicine Chilean Congress, Santiago, Chile, 1994

Invited Speaker, "Prevention of diabetes:  Is it possible? ", XVI Internal Medicine Chilean Congress, Santiago, Chile, 1994

Invited Speaker, "Insulin Analogs" American Diabetes Association, Northern Illinois Affiliate’s Thirty-Seventh Annual Professional Symposium, Chicago, 1994

Invited Speaker, "The Translation of the DCCT to the Care of the Patient with Type II Diabetes Mellitus", The Third Annual Controversies in Ambulatory Care Medicine, Philadelphia, 1994

Visiting Professor, "Prevention of Type II Diabetes:  The Challenge of the Next Decade", Medical Grand Rounds, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ, 1995

Visiting Professor, “The Promotion of the Adipocyte:  from storage to an endocrine cell”, Grand Rounds, University of Southern California School of Medicine, Los Angeles, CA, 1995

Visiting Professor, “¿Es el adiosito inteligente?”, Consejo Superior de Investigaciones Científicas, Madrid, Spain, 1995

Leadership Workshop:  "Insulin Action Enhancers”, 55th Annual Meeting, American Diabetes Association, Atlanta, Georgia, 1995

Invited Speaker, “Impact of weight loss by surgery on metabolic fitness”, FASEB Summer Conference on Genetic and Behavioral Influences on Nutrient Metabolism and Obesity, Copper Mountain, Colorado, 1995

Visiting Professor, “Ob protein resistance in human obesity”, University of Chicago, Chicago, Illinois, 1995

Plenary Speaker, “Studies of Leptin in Human Subjects”, NAASO Meeting, Baton Rouge, Louisiana, 1995

Symposium Speaker, “The Gut and NIDDM”, Precose Specialist Investigator Meeting, Lincolnshire, IL, 1995

Visiting Professor, “¿Terapia molecular de la diabetes o de la obesidad?”, V Congreso de Ciencias Farmacéuticas, Madrid, Spain, 1995

Symposium Speaker, “Obesidad e insulino resistencia”, Sociedad Mexicana de Nutrición y Endocrinologia, Guanajuato, Mexico, 1995

Symposium Speaker, “Leptin:  The sensor of either fact mass or energy balance?”, American Society for Parenteral and Enteral Nutrition, Washington, DC, 1996

Symposium Speaker, “Advances en Fisiopatologia de la Obesidad”, Canary Islands, Spain,1996

Invited Speaker, “The Ob Gene in Human Obesity”, Western Metabolism Club, Carmel, CA, 1996

Invited Speaker, “Ob Protein in Human Obesity”, IBC’s Second Annual International Symposium, Washington, DC, 1996

Invited Speaker, “New Insights into the Pathophysiology and Therapy of Obesity:  The Leptin Story”, Sixteenth Meeting of the International Scientific Committee on Diabetes, Cologne, Germany, 1996

Invited Speaker, “Obesity:  A Genetic Disease?”, Fourth Scientific Course in Pancreatic Islet Physiology and Pathology, Barcelona, Spain, 1996

Invited Speaker, “Obesity:  What Can be Done?”, Clinical Endocrinology, Harvard Medical School, Boston, MA, 1996

Invited Speaker, "Human Obesity:  What Have We Learned from Recent Genetic Insights?",  Biomedicine '96, Washington, D.C., 1996

Visiting Professor, "Leptin:  The Tale of an Obesity Gene, Part II:  Rx:  Leptin Sc, qday and eat anything you want , East Carolina University, Greenville, NC, 1996

Invited speaker, "Leptin Physiology and Pathophysiology in Man", American Society for Clinical Investigation, Washington, D.C., 1996

Symposium Speaker, "Molecular therapy of obesity or diabetes?  That is the question", XIII Meeting of the Spanish Diabetes Society, Oviedo, Spain, 1996

Keynote speaker, "Leptin:  The tale of an obesity gene: American Diabetes Association, Amelia Island, Florida, 1996

Symposium Speaker: “Obesity and Diabetes” 4th Annual Congress on Women’s Health, Washington, D.C., 1996

Invited Speaker, “Leptin: The Tale of an Obesity Gene” Annual Research Symposium, The Institute of Nutrition, University of North Carolina, Chapel Hill, NC, 1996

Invited Speaker, “Ob Protein in Human Obesity”  IBC’s Third International Symposium - Obesity - Advances in Understanding and Treatment. San Diego, CA, 1996

Invited Speaker, “Meeting the Needs of patients: Emerging Options in Diabetes Care”.  34th Annual Meeting of the European Association for the Study of Diabetes. Vienna, Austria, 1996

Invited Speaker. “Obesity as a Metabolic Disease”.  6th Annual Turamberry Conference. Aventura, Florida, 1996

Invited Speaker.  “The ob Gene Product and Nutrient Balance”. North American Association for the Study of Obesity. Breckenridge, Colorado, 1996

Invited Speaker.  XXVI Congreso de la Asociación Española de Pediatria. Valencia, Spain, 1996

Invited Speaker.  Human Obesity: Beyond Leptin Production. International Congress on Anti-Obesity Drug Targets. Cambridge, MA., 1996

Invited Speaker.  Insulina y leptina: La Extraña Pareja. VIII Congreso Sociedad Valenciana de Endocrinologia, Diabetes y nutrición. Valencia, Spain, 1996 

Invited Speaker.  Chapter One in the Story of Leptin in Humans. American Society for Clinical Pharmacology and Therapeutics. San Diego, CA, 1997

Invited Speaker.  “Pathophysiology of Obesity”.  Symposium of the German Endocrine Society. Lübeck, Germany, 1997.

Invited Speaker.  “Leptin: The Second Year”.  2nd World Conference of the International Society for Molecular Nutrition and Therapy.  Winnipeg, Canada, 1997.

Invited Speaker.  "Leptin: From Rodents to Humans".  International Diabetes Federation Congress, Helsinki, Finland, 1997

Invited Speaker.  “Leptin: The New Lean Gene”.  European Congress of Clinical Chemistry “Medlab97”, Basel, Switzerland, 1997

Invited Speaker.  Grand Rounds.  "Leptin: From Rodents to Humans".  Tulane University, New Orleans, Louisiana, 1997

Invited Speaker, Plenary Session.  "Current and Future Implications For the Use of Leptin in the Treatment of Obesity".  NAASO Annual Meeting, Cancun, Mexico, 1997

Invited Speaker, Conferencia  “Diabetes, obesity y leptin”.  Simposia Harvard - Joslin - SBD, XI Congreso Brasileño de Diabetes, Porto Alegre, Brazil 1997

Medical Grand Rounds - “The Role of Leptin in Body Weight Regulation”.  The University of Texas. San Antonio, TX, 1997

Research Seminar: “Strategies for the treatment of type II diabetes”.  Garvan Institute. Sydney, Australia, 1997

Research Seminar: “Recent Advances on Leptin”.  The Walter and Eliza Hall Institute for Medical Research.  Melbourne, Australia, 1997

Plenary Lecturer: “Strategies for the treatment of Obesity”.  NAASO and American Society of Clinical Nutrition.  Merida, Mexico, 1997

Congreso Nacional de la Sociedad Española de Diabetes y Obesidad: “Leptina y obesidad".  Caceres, Spain, 1997

Invited Speaker - Bio-chemistry Seminar: “Strategy of drug discovery for the treatment of obesity”.  Indiana University Medical Center.  Indianapolis, IN, 1998

Invited Speaker: American Diabetes Association “Leptin Pathway as a Target for Treatment”.  San Francisco, California, 1998

Invited Speaker: “Addressing the Accelerating Cost of Chronic Diseases:  A Case Study”.  Meeting the 21st century healthcare challenge:  A New Vision for Pharmaceutical Innovation.  PHRMA, U.S. Embassy. Tokyo, Japan, 1998

Opening Lecture of the XIV Sociedad Española de Diabetes: “En el camino a la cura de la Diabetes” Murcia, Spain, 1998

Keynote lecture: “A new endocrine cell: Biology and Function of Adipocytes” 71st Annual Meeting of the Japan Endocrine Society.  Fukuoka, Japan, 1998

Plenary lecture: “Leptin: the Past, Present and Future”.  71st Annual Meeting of the Japan Endocrine Society.  Fukuoka, Japan, 1998

Plenary lecture: “From New Genes to New Treatments”.  Satellite Symposium of the 8th International Congress on Obesity.  Paris, France, 1998

Plenary lecture: “Emerging Therapies for Type II Diabetes”.  34th Annual Meeting of the European Association for the Study of Diabetes.  Barcelona, Spain, 1998

Conferencia Magistral - Hospital Maciel: “ Leptina la Voz Del Adiosito”. Simposio Obesidad y Diabetes Mellitus - Cuando Y Como Intervenir. Montevideo, Uruguay, 1998

Conferencia Magistral - Hospital Maciel: “Intervenciones Futuras en el Manejo de la Obesidad.  Montevideo, Uruguay, 1998

Lilly Symposium - Temas actuales en Diabetes. “Leptina y Obesidad”. Montevideo, Uruguay, 1998

Invited Speaker: “Opciones terapéuticas en el síndrome de insulinorresistencia”.  XI Congreso Argentino de Diabetes.  Cordoba, Argentina, 1998

Invited Speaker: “Leptina y Obesidad”.  XI Congreso Argentino de Diabetes.  Cordoba, Argentina, 1998

Opening Lecture: “Leptina: La voz del Adiosito”.  III Curso Sobre Investigaciones Biomedicas, Universidad de Granada y Consejo Superior de Investigaciones Científicas.  Granada, Spain, 1998

Symposium Speaker:  “New Molecular Target for the treatment of Obesity”.  “VI Meeting on Lipid Metabolism and Related Pathology”  Instituto Superior de Ciencias da Sande-Sul.  Costa da Caprica, Portugal, 1998

Symposium Chairman and Speaker:  “Neuroendocrine integration of appetite".  Experimental Biology ‘99 Meeting.  Washington, D.C. 1999

Invited Speaker: "Leptin: The tale of an obesity gene and it's application to children".  Building Bright Futures: Neonatal, Pediatric and Adolescent Nutrition in the 21st Century.  Indiana University School of Medicine, Indianapolis, IN.  1999

Symposium Co-Chairman and Speaker.  "On the trail to cure obesity".  Genetics, Pathophysiology and Therapeutics on the Eve of a Major Conceptual Revolution.  Euro-Conference Institute Pasteur.  Paris, France, 1999

Invited Speaker: "Insulin Resistance: A target for drug therapy at the CMES Ancillary Symposium, The Endocrine Society.  Toronto, Canada, 2000

Visiting Professor:  “New targets for the treatment of obesity”.  Medical Grand Rounds, University of Pittsburgh School of Medicine.  Pittsburgh, PA.  2001

Invited Speaker:  “The treatment of diabetes in the new Millennium.  Italian Society of Diabetes.  Florence, Italy, 2002

Symposium Speaker:  “New Drug Therapies for Obesity” at Obesity:  Molecular Causes

and New Pathways for Treatment and Prevention.  American Association for the Advancement of Science (AAAS) Annual Meeting.  Denver, Colorado.  2003

Keynote Speaker:  “The Do’s and Do Not’s in Science:  From Fuller Albright to the Present”. Graduate Student Research Day.  East Carolina University. Greenville, NC.  2003

Symposium Speaker:  “Obesity and the Metabolic Syndrome:  Identifying Underlying Mechanisms and Emerging Therapies for Pharmacological Treatment”.  Pharmaceutical Education Associates.  Washington, DC.  2003.

Roundtable Participant:  “Obesity and Cancer” National Dialogue on Cancer.  Sponsored by President George W. and Barbara Bush.  Kennebunkport, Maine.  2003

Keynote Speaker and Chairperson:  “Opportunities and Challenges of Therapeutic Development for Obesity”.  World Obesity Congress & Expo.  Washington, DC.  2004

Symposium Speaker:  “Addressing the Obesity Epidemic:  From Bench to Bedside to Market”.  The Endocrine Society’s 86th Annual Meeting.  New Orleans, LA.  2004

Invited Speaker:  “Overcoming Diabetes:  A Long March from Discovery to Commercialization”.  The Opening Ceremony of the Peking University Diabetes Center.  Beijing, China.  2004

Invited Speaker:  “Anti-Obesity Drug Development:  From Target Identification to Launch”.  NAASO 2004 Scientific Meeting.  Las Vegas, NV.  2004

Invited Speaker:  “New Therapies for Diabetes”.  Leerink Swann/MEDACorp. Inaugural Health Care Conference.  New York, NY.  2005

Invited Speaker:  “Insulin Sensitivity Enhancers for the Treatment and Prevention of Diabetes“ Diabetes and Obesity Research Day.  East Carolina University, Brody School of Medicine.  Greenville, NC.  2005

Keynote Speaker and Chairperson:  “New Opportunities and Challenges of Therapeutic Developments with Obesity and Weight Loss”.  World Obesity Congress & Expo.  Washington, DC.  2005

Keynote Speaker:  “On the Trail to ARREST the Progression of Type 2 Diabetes”  College of Agriculture and Life Sciences, University of Arizona.  Phoenix, AZ.  2005

Keynote Speaker:  “On the Trail to ARREST the Progression of the Metabolic Syndrome”  8th Symposium Fundacion Lilly “New Approaches to the Metabolic Syndrome”  San Lorenzo de El Escorial, Madrid.  2005

Invited Speaker: “May be difficult at times…?” At The 5th National Metabolic Day. Utrecht University,  Amsterdam, The Nederland 2006

Keynote Speaker: “Diabesity” 13th Annual Kaiser Permanente Diabetes Symposium. Woodland Hills, CA  2007

 

Invited Speaker  and panel member: “Clinical Trials, Setting the stage for the future”. At the inaugural Clinical Trial Regional Exchange Group, The North Carolina Biotechnology Center. Greenville NC, 2007

Post Graduate Course in Endocrinology: “Obesity”. At the Universidad Catolica, Montevideo, Uruguay, 2008

Invited Speaker: “Peers for Progress”. At the School of Medicine, Maciel Hospital. Montevideo, Uruguay, 2008


Publications

1.          Caro, J.F., A. Besarab, J.R. Burke, and J.A. Glennon.  Propranolol: A possible role in the treatment of renal osteodystrophy. Lancet         I             I:451,1978.

2.          Caro, J.F., and A. Besarab. Propranolol therapy for hyperparathyroidism. Lancet II:827,1978.

3.          Caro, J.F., A.W. Meikle, J.H. Check, and S.N. Cohen. "Normal suppression" to dexamethasone in Cushing's disease: An expression of                 decreased metabolic clearance for dexamethasone. J. Clin. Endocrinol. Metab. 47:667,1978

4.          Ballas, S.K., J.F. Caro, and O. Miguel. Quinidine-induced hemolytic anemia: Immunohematologic characterization. Transfusion                             18:215,1978.

5.          Besarab, A., and J.F. Caro. Mechanism of hypercalcemia in malignancy. Cancer 6:2276,1978.

6.          Caro, J.F., A. Besarab, and J.A. Glennon.  Symptomatic hypocalcemia following combined calcitonin and mithramycin therapy for                        hypercalcemia in malignancy. Cancer Treat Reports 62:1561,1978.

7.          Check, J.H., J.F. Caro, L. Jackson, K. Nowroozn and A.F. Rakoff.  Clinical mixed gonadal dysgenesis without Y chromosome. Am. J.                     Obstet. Gynecol. 131:346,1978.

8.          Check, J.H., J.F. Caro, and J.T. Flynn. Cystic gynecomastia in a male treated with clomiphene citrate. Infert. Sterility 30:713,1978.

9.          Caro, J.F., A. Besarab, and J.T. Flynn. Prostaglandin E and hypercalcemia in breast carcinoma: Only a tumor marker? A need for                           prospective. Am. J. Med. 66:337,1979.

10.       Caro, J.F., H.L. Israel, and J.A. Glennon. Galactorrhea in sarcoidosis: Dynamic studies of prolactin, growth and gonadotropic hormone                levels. Am. J. Med. Sci. 277:1,1979.

11.       Check, J.H., J.F. Caro, B. Kendall, L.A. Peris, and B.L. Wellenback. Cushing's syndrome in pregnancy: Effect of associated diabetes on                 fetal and neonatal complications. Am. J. Obstet. Gynecol. 44:846,1979.

12.       Check, J.H., J.F. Caro, L. Criden, R. Meltz, and K. Brownstein. Leyding cell responsiveness with gonadal cell resistance to                                      gonadotropin therapy in Kallman's syndrome. Am. J. Med. 67:495,1979.

13.       Caro, J.F., J.H. Castro, and J.A. Glennon. Effect of long-term propranolol administration on parathyroid hormone and calcium                                concentration in primary hyperparathyroidism. Ann. Int. Med. 91:740,1979.

14.       Caro, J.F., N.G. Sloane, and J.A. Glennon. Hyperthyroidism with normal serum T4, T3 and TBG immunoreactivity. J. Clin. Pat.                               33:868,1980.

15.       Caro, J.F., and P.D. Woolf. Pituitary-ovarian axis responsitivity to prolonged GnRH infusion in normal and hyperprolactinemic women.                J. Clin. Endo. Metab. 50:999,1980.

16.       Insogna, K.L., D.R. Bordley, J.F. Caro, and D.H. Lockwood. Osteomalacia and weakness due to excessive antacid ingestion. J.A.M.A.                  244:2544,1980.

17.       Castro, J.H., J.F. Caro, Kim, and J.A. Glennon. Effects of PTH infusion in primary hyperparathyroidism on plasma prolactin in man. J.                   Clin. Endo. Metab. 51:397,1980. 

18.       Caro, J.F., and J.M. Amatruda. Functional relationship between insulin binding, action and degradation. J. Biol. Chem.                                            255:10052,1980.

19.       Caro, J.F., and J.M. Amatruda. Insulin receptors in hepatocytes: Post receptor events mediate down regulation. Science                                          210:1029,1980.

20.       Caro, J.F., and J.M. Amatruda.  The effects of fasting on glucagon binding and action in isolated hepatocytes. Metabolism 29:732,1980.

21.       Caro, J.F. and J.A. Glennon, and H.L. Israel.   Neuroendocrine studies in sarcoidosis.  William, J.W. and Davis, B. H. (Eds.), Alpha                        Omega Publ. pp.587,1980.

22.       Cech, J.N., R.B. Freeman, J.F. Caro, and J.M. Amatruda. Insulin action and binding in isolated hepatocytes from fasted, streptozotocin               diabetic and older, spontaneously obese rats. Biochem. J. 188:839,1980.

23.       Caro, J.F., and J.M. Amatruda. Evidence for the modulation of insulin action and degradation independently of insulin binding. Am. J.                  Physiol. 240:E325,1981.

24.       Besarab, A., J.F. Caro, B.U. Ihle, J.F. Burke, and J.A. Glennon. Suppression of secondary hyperparathyroidism by propranolol in renal               failure patient. Nephron 27:127,1981.

25.       Besarab, A. and  J.F. Caro.  Increased absolute calcium binding to albumin in hypoalbuminaemia.  J. Clin. Path. 34:1368,1981.

26.       Basal, S., P.D. Woolf, J.A. Fischer, and J.F. Caro. Dopamine does not affect parathyroid function in man. J. Clin. Endo Metab.                                  54:651,1982.

27.       Caro, J.F., and J.M. Amatruda. The regulation of lipid synthesis in freshly isolated hepatocytes and primary cultures of hepatocytes from              fasted rats: The primary role of insulin. Metabolism 31:14,1982.

28.       Caro, J.F., and J.M. Amatruda. Glucocorticoid-induced insulin resistance: The importance of post receptor events in the regulation of                    insulin binding and degradation. J. Clin. Invest. 69:866,1982.

29.       Caro, J.F., G. Muller and J.A. Glennon. Insulin processing by the liver. J. Biol. Chem. 257:8459,1982.

30.       Kauffman, J.M., and J.F. Caro. Insulin resistance in uremia: Characterization of insulin action binding and processing in isolated                            hepatocytes from chronic uremic rat. J. Clin. Invest. 71:698,1983.

31.       Caro, J.F., and S. Jacoby. Lipid synthesis in freshly isolated and primary culture of rat hepatocytes from chronic uremic rats. J. Clin.                      Invest. 72:882,1983.

32.       Caro, J.F., F. Folli, F. Cecchin, and M.K. Sinha. Chemical mediator of insulin action stimulates lipid synthesis and down regulates the                  insulin receptors in primary cultures of rat hepatocytes. Biochem. Biophys. Res. Commun. 115:375,1983.

33.       Helineck, T.G., S. Sadel, and J.F. Caro. The effect of chronic uremia on glucagon binding and action in isolated rat hepatocytes.                            Metabolism 33:158,1984.

34.       Caro, J.F., F. Cecchin, and M.K. Sinha. Is glycosylation in the liver needed for insulin binding, processing, and action: evidence for                        heterogeneity. J. Biol. Chem. 259:12810,1984.

35.       Sinha, M.K., and J.F. Caro. Presence of an activator of pyruvate dehydrogenase in human circulation: elevation following a glucose                    load and possible relation to an insulin mediator. Biochem. Biophys. Res. Commun. 129:41,1985.

36.       Chaplinski, T.J., T.E. Bennett, and J.F. Caro. Alteration in insulin receptor expression accompanying differentiation of HL-60 leukemia                   cells. Cancer Research 46:1203,1986.

37.       Caro, J.F., O. Ittoop, W.J. Pories, D. Meelheim, E.G. Flickinger, F. Thomas, M. Jenquin, J.F. Silverman, P.G. Khazanie, and M.K. Sinha.                  Studies on the mechanism of insulin resistance in the liver from humans with non-insulin-dependent diabetes; insulin action and                          binding in isolated hepatocytes, insulin receptor structure and kinase activity. J. Clin. Invest. 78:249,1986.

 38.       Folli, F., M.K. Sinha, D. Brancaccio, and J.F. Caro. Insulin resistance in uremia: In vitro model in the rat liver using human serum to                       study mechanism(s). Metabolism 35:989,1986.

 39.       Dohm, G.L, J.F. Caro, and T. Fushiki. Mechanisms(s) responsible for increased glucose uptake during exercise. I.R.C.S. Med Sci                         14:1174,1986.

 40.       Dohm, G.L., M.K. Sinha, J.F. Caro. Insulin receptor binding and protein kinase activity in muscles of trained rats. Am. J. Physiol.                            252:E170,1987.

 41.       Caro, J.F.  Non-Insulin-Dependent Diabetes Mellitus in Hispanic Americans, A Roundtable Discussion, Upjohn, Publication No.  .

 42.       Sinha, M.K., W.J. Pories, E.G. Flickinger, D. Meelheim, and J.F. Caro. Insulin receptor kinase activity of adipose tissue from morbidly                     obese humans with or without noninsulin-dependent diabetes. Diabetes 36:620,1987.

 43.       Caro, J.F., W.J. Pories, E.G. Flickinger, D. Meelheim, O. Ittoop, M. Jenquin, M.K. Sinha, and G.L. Dohm. Insulin receptor kinase in human skeletal muscle from obese subjects with and without non-insulin dependent diabetes. J. Clin. Invest. 79:1330,1987.

 44.       Forsayeth, J.R., J.F. Caro, M.K. Sinha, B.A. Maddux, and I.D. Goldfine. Monoclonal antibodies to the human insulin receptor that activate glucose transport but not insulin receptor kinase activity. Proc. Nat. Acad. Sci (USA) 84:3448,1987.

 45.       Caro, J.F., M.K. Sinha, and G.L. Dohm. Effect of chronic uremia on fructose 2,6-bisphosphate glycolytic and gluconeogenic enzymes in rat liver. Biochem. Biophys. Res. Commun. 144:352,1987.

 46.       Pories W.J., J.F. Caro, E.G. Flickinger, H.D. Meelheim, and M.S. Swanson. The control of diabetes mellitus (NIDDM) in the morbidly obese with the Greenville Gastric Bypass. Annals of Surgery 206:316,1987.

 47.       Sinha, M.K., L.G. Taylor, W.J. Pories, E.G. Flickinger, D. Meelheim, S. Atkinson, N.S. Sehgal, and J.F. Caro. Long-term effect of insulin on glucose transport and insulin binding in cultured adipocytes from normal and obese humans with and without non-insulin dependent diabetes. J. Clin. Invest 80:1073,1987.

 48.       Caro, J.F., J.A. Shafer, S.I. Taylor, S.M. Raju, N. Perrotti, and M.K. Sinha. Insulin stimulated protein phosphorylation in human plasma liver membranes: detection of endogenous or plasma membrane associated substrates. Biochem. Biophys. Res. Commun. 149:1008,1987.

 49.       Dohm, G.L., E.B. Tapscott, W.J. Pories, D.J. Dabbs, E.G. Flickinger, D. Meelheim, T. Fushiki, S.M. Atkinson, and J. F. Caro. An in vitro human muscle preparation suitable for metabolic studies. Decreased glucose transport in muscle from morbidly obese subjects. J. Clin. Invest. 82:486,1988.

 50.       Caro, J.F., J. Poulos, O. Ittoop, W.J. Pories, E.G. Flickinger and M.K. Sinha. Insulin-like growth factor I binding in hepatocytes from human liver, human hepatoma, and regenerating and fetal rat liver. J. Clin. Invest. 81:976,1988.

 51.       Cecchin, F., O. Ittoop, M.K. Sinha and J. F. Caro. Insulin resistance in uremia: Insulin receptor kinase activity in liver and muscle from chronic uremic rats. Am. J. Physiol. 254:E394,1988.

 52.       Caro, J.F., F. Cecchin, F. Folli, C. Marchini, and M.K. Sinha. Effects of T3 on insulin action, insulin binding and insulin receptor kinase activity in primary cultures or rat hepatocytes. Horm. Metab. Res 20:327,1988.

53.       Misbin, R.I., A. Green, I.M. Alverz, E.C. Almira, G.L. Dohm, and J.F. Caro. Inhibition of insulin stimulated glucose transport by a factor extracted from the serum of a patient with insulin resistance. Diabetes 37:1217,1988.

54.       Caro, J.F., S.M. Raju, M.K. Sinha, I.D. Goldfine, and G.L. Dohm. Heterogeneity of 5human liver, muscle, and adipose tissue insulin receptor. Biochem. Biophys. Res. Commun. 151:123,1988.

55.       Goldfine, I.D. and J.F. Caro.  Molecular and Cellular Biology of the Insulin Receptor in Diabetes Mellitus. In:  Molecular and Cellular Biology of Diabetes Mellitus, Vol II.  B Draznin, S. Melmed and D. LeRoith, (Eds.) Alan R. Liss, Inc., New York, pp.11,1989.

 56.       Silverman, JF., W. J. Pories, J.F. Caro.  Liver Pathology in Diabetes Mellitus and Morbid Obesity:  Clinical, Pathologic, and Biochemical Considerations. S. Sommers, P.P. Rosen, and R.E. Fechner (Eds).  Appleton & Lange. Pathology Annual 24:275,1989.

 57.       Caro, JF., G.L.Dohm, W.J. Pories, and M.K. Sinha.  Cellular Alterations in Liver, Skeletal, Muscle, and Adipose Tissue Responsible for Insulin Resistance in Obesity and Type II Diabetes.  Diabetes Metabolism Review 5:665,1989.

 58.       Contreras, N.I. and J.F. Caro.  The Collisional Hypothesis of Insulin Action, Receptor Internalization and Diabetes.  TIBS 14:399,1989.

 59.       Thakkar, J.K., R. DiMarchi, K. MacDonald and J.F. Caro. Effect of insulin and insulin-like growth factors I and II on phosphatidylinositol and phosphatidylinositol-4.5-biophosphate breakdown in liver plasma membranes from humans with and without type II diabetes. J. Biol. Chem. 264:7169,1989.

 60.       Caro, J.F., O. Ittoop, and M.K. Sinha. Glyburide but not ciglitazone enhances insulin action in the liver independent of insulin receptor kinase activation. Metabolism 38:606,1989.

 61.       Sinha, M.K., C. Buchanan, N. Leggett, L. Martin, P.G. Khazanie, R. DiMarchi, W.J. Pories, and J.F. Caro. Mechanism of IGF-I stimulated glucose transport in human adipocytes: demonstration of specific IGF-I receptors not involved in stimulation of glucose transport. Diabetes 38:1217,1989.

62.       Caro, J.F., G.L. Dohm, and M.K. Sinha. Insulin Resistance in Obesity. Adv. Diabetologia 2:1,1989.

63.       Moller, D.E., A. Yokota, J.F. Caro, and J.S. Flier. Tissue-specific expression of two alternatively spliced insulin receptor mRNAs in man. Molecular Endocrinology 3:1263,1989.

 64.       Caro, J.F., M.K. Sinha, and G.L.Dohm.  Insulin Resistance in Obesity.  In:  Obesity Towards a Molecular Approach.  Alan R. Liss, Inc., New York. Vol. 132:203,1990.

 65.       Marcuard, S.P., B. Dunham, A. Hobbs, and J.F. Caro. Availability of insulin from total parenteral nutrition (TPN) solutions. J. Parent Enter Nutri. 14:262,1990.

 66.       Caro, J.F.  "Mechanisms de accion de la insulina y resistencia a la insulina en la obsidad y diabetes tipo 2."  In:  Los islotes de Langerhans:  un organo multiendocrino. (Enrique Blazquez y Jorge Tamarit, eds.), Fundacion Romon Areces, pp.203,1990.

67.       Thakkar, J.K., M.S. Raju, and J.F. Caro. 3H Myoinositol incorporation into phospholipids in liver microsomes from humans with and without Type II diabetes: The lack of synthesis of glycosyl-phosphatidyl inositol, precursor of the insulin mediator inositol phosphate glycan. J. Biol Chem. 265,10:5475,1990.  

68.       Dohm, G.L., W. Elton, S.M. Raju, N. Mooney, R. DiMarchi, W.J. Pories, E.G. Flickinger, S.M. Atkinson, and J.F. Caro. IGF-I stimulated glucose transport in human skeletal muscle and IGF-I resistance in obesity and NIDDM. Diabetes 39:1028,1990.

69.       Contreras, I., G.L. Dohm, S. Abdallah, A. Wells, N. Mooney, A. Rovira, and J.F. Caro. The effect of fasting on in vivo activation of the insulin receptor tyrosine kinase. Biochem. J. 265:887,1990.

70.       Burguera, B., H. Werner, M. Sklar, Z Shen-Orr, B. Stannard, C.T. Roberts, Jr., S.P. Nissley, S.J. Vore, J.F. Caro, and D. LeRoith. Liver regeneration is associated with increased expression of the insulin-like growth factor II/mannose-6-phosphate receptor. Molecular Endocrinology 4:1539,1990. 

71.       Sinha, M.K. and J.F. Caro. Effect of insulin and tunicamycin on insulin receptor kinase activity in primary cultures of rat hepatocytes. Endocrinologia 37:18,1990. 

72.       Silverman, J.F., K. O'Brien, S. Long, N. Leggett-Frazier, P.G. Khazanie, W.J. Pories, H.T. Norris, and J.F. Caro. Liver pathology in morbidly obese patients with and without diabetes. Am. J. Gastroenter. 85:1349,1990.

73.       Sinha, M.K., C. Buchanan, C. Raineri-Maldonado, P. Khazanie, S. Atkinson, R. DiMarchi, and J.F. Caro. IGF-II receptors and IGF-II stimulated glucose transport in human fat cells. Am. J. Phys. 258:E534,1990.

74.       Poulus, J.F., E.L. Treadwell, K. O'Brien, S. Long, and J.F. Caro. The presence of autoantibodies to the IGF-I, IGF-II and insulin receptor in patients with Type II (noninsulin-dependent) diabetes, impaired glucose tolerance and autoimmune diseases.  Adv. Diabetologia 3:83,1990.

75.       Caro, J.F. Effects of glyburide on carbohydrate metabolism and insulin action in the liver. Am J. Med. 89:17,1990.

76.       Chen, J.J., H.Y. Lee, and J.F. Caro.Contribution of non-insulin-dependent diabetes mellitus to the insulin metabolic clearance rate of morbidly obese patients. Clin. Med. J. (Taipei) 45:285,1990.

77.       Burguera, B. and J.F. Caro. Mechanism of action of insulin: first chapter. Endocrinologia 37:1,1990.

78.       Barakat, H.A., V.D. McLendon, J.W. Carpenter, R.H.L. Marks, N. Leggett, K. O'Brien, and J.F. Caro. Lipogenic potential of liver from morbidly obese patients with and without noninsulin-dependent diabetes. Metabolism 40:280,1991.

79.       Chen J.J., N. Leggett, K.O'Brien, S. Long, P.G. Khazanie, G.L. Dohm, M.K. Sinha, H.A. Barakat, W.J. Pories and J.F. Caro.  "Insulin action in obesity and diabetes."  In:  Progress in Obesity Research. John Libbey and Company Ltd.,London, England, Chapter 57, pp.365,1991.

80.       Caro, J.F., S.R. Madhu, J.C. Hale, N. Leggett-Frazier, S. Long, W.J. Pories.  Altered coupling of the insulin receptor with G1 protein in the liver from patients with NIDDM.  New Directions in Research and Clinical Works for Obesity and Diabetes Mellitus  In:  Excerpta Medica International Congress Series, Elsevier Science Publishers, pp.53,1991.

81.       Sinha, M.K., C. Raineri-Maldonado, C. Buchanan, W.J. Pories, C.C. Su, P.F. Pilch, and J.F. Caro. Adipose tissue glucose transporters in non-insulin-dependent diabetes mellitus: decreased levels of muscle/fat and erythroid isoforms. Diabetes 40:472,1991.

82.       Caro, J.F., J. Hodges, and M.K. Sinha. Increased insulin responsiveness in hepatocytes incubated with free fatty acid-poor albumin. Horm. Metab. Res. 23:362,1991.

83.       Friedman, J.E., R.W. Dudek, D.S. Whitehead, D.L. Downes, W.R. Frisell, J.F. Caro, and G.L. Dohm. Immunolocalization of glucose transporter Glut4 with human skeletal muscle. Diabetes 40:150,1991.

84.       Dohm, G.L., C.W. Elton, J.E. Friedman, P.F. Pilch, W.J. Pories, S.M. Atkinson, Jr., and J.F. Caro. Decreased expression of glucose transporter in muscle from insulin resistant patients. Am. J. Physiol. 260:E459,1991.

85.       Friedman, J.E., G.L. Dohm, C.W. Elton, A. Rovira, J.J. Chen, N.L. Frazier, S.M. Atkinson Jr., S.D. Long, and J.F. Caro. Muscle insulin resistance in uremic humans: Glucose transport, glucose transporters, and insulin receptors. Am. J. Physiol. 261:E87,1991.

86.       Caro, J.F. Insulin resistance in obese and non-obese man. J. Clin. Endo Metab. 73:691,1991.

87.       Burguera, B. and Caro, J.F.  Alterations in insulin receptors and glucose transporters in obesity and Type 2 diabetes.  In: Frontiers in Diabetes Research. Lessons from Animal Diabetes III. Eleazar Shafrir (Ed.), Smith-Gordon and Company, Ltd. pg. 269,1991.

88.       Burguera B., Long S., Frank H.B., DiMarchi R., Caro, J.F.  Binding of insulin-like growth factors, proinsulin and proinsulin analogs to human liver, muscle and adipose tissue receptors.  J. Clin. Endocrinol. Metab. 72:1238,1991.

89.       Burguera B, Madigan T., Mustafa, S.J., Frank, H.B., DiMarchi, R. and Caro J.F.   The interaction of proinsulin with insulin-like growth factors I and II receptors in smooth muscle membranes from bovine coronary arteria.  Av Diabetol 5:187,1992.

90.       Freidman, J.E., G.L. Dohm, N. Leggett-Frazier, C.W. Elton, E.B. Tapscott, W.P. Pories, and J.F. Caro.  Restoration of insulin responsiveness in skeletal muscle of morbidly obese patients after weight loss:  Effect on muscle glucose transport and glucose transporter GLUT-4.  J. Clin. Invest. 89:701,1992.

91.       Burguera, B., H. Werner, M.Couce, D. LeRoith, J.F. Caro.  Regulation of IGF's receptor.  Regulation of growth hormone and somatic growth.  LF de la Cruz (Ed.)  Elsevier Amsterdam. pp.271,1992.

92.       Caro, J.F.  Mecanismos de la Accion de la insulina y resistencia a la insulina en la obesidad y diabetes tipo II.  J Latino Amer. Soc. Diab.  14:10,1992.

93.       Pories, W.J., K.G. MacDonald, E.J. Morgan, M.K. Sinha, G.L. Dohm, M.S. Swanson, H.A. Barakat, P.G. Khazanie, N. Leggett-Frazier, S. D. Long, K.F. O'Brien, and J.F. Caro. Surgical treatment of obesity and its effect on diabetes: 10-y follow-up. Am. J. Clin. Nutr. 55:582S,1992.

94.       Caro, J.F., M. Jenquin, S. Long. Effects of phorbol esters on insulin receptor function and insulin action in hepatocytes: evidence for heterogeneity. Mol. Cell Biochem. 109:115,1992.

95.       Contreras, I., J.F. Caro, L. Aveledo, K. Diaz, P. Durrego, and J.R. Weisinger. In Chronic uremia, insulin activates receptor kinase but not pyruvate dehydrogenase. Nephron. 61:71,1992.

96.       Pories, W.J., K.G. MacDonald, E.G. Flickinger, G.L. Dohm, M.K. Sinha, H.A. Barakat, H.J. May, P. Khazanie, M.S. Swanson, E. Morgan, N. Leggett-Frazier, S.D. Long, B.M. Brown, K. O'Brien, and J.F. Caro. Is type II diabetes mellitus (NIDDM) a surgical disease? Ann. Surg. 251:633,1992.

97.       Usala, A.L., Madigan, T., Burguera, B., Sinha, M.L., Caro, J.F., Powell, J.G., and Butler, P.C. Brief Report:  Treatment of insulin resistance diabetic ketoacidosis with insulin-like growth factor I in an adolescent with insulin-dependent diabetes. New England Journal of Medicine. 327:853,1992.

98.       Caro, J.F.  Diabetes and Hypertension:  Not the Final Chapter.  Diabetes Care.  16:540,1992.

99.       Barakat, H.A., N. Mooney, K. O'Brien, S. Long, P. Khazanie, W.J. Pories, and J.F. Caro. Coronary artery disease risk factor in morbidly obese women with normal glucose tolerance. Diabetes Care.  16:144,1992.

100.     Considine, R.V. and Caro, J.F.  Protein Kinase C:  Mediator or Inhibitor of Insulin Action?  J Cell Biochem.  52:1,1992.

101.     Serrano, J., C.M. Mateo and J.F. Caro. Insulin resistance:  Cellular and molecular mechanisms.  In:  Recent Advances in Endocrinolgoy and Metabolism.  Vol. 4. C.R.W. Edwards and D.W. Lincoln (Eds.), Churchill Livingstone, London, UK.  Chapter 11.pp.167,1992.

102.     Burguera, B., Couce, M.E., Caro, J.F.  Fisiologia del receptor insulin-like growth factor-II/manosa 6 fosfato (IGF-II/Man 6-P R).  In:  Advances en Endocrinologia Celular Y Molecular. F.F. Casanueva, C. Dieguez, (Eds.), Fundacion Ramon Areces. pp.221,1992.

103.     Burguera, B., H. Werner, M. Couce, C.T. Roberts, D. LeRoith, J.F. Caro.  Physiology of the Insulin-Like Growth Factor I and Insulin-Like Growth Factor II/Mannose 6-Phosphate Receptors.  LF de la Cruz (Ed.) Elsevier Amsterdam. pp.271,1992.

104.     Burguera, B., Parzianella, N.A., Caro, J.F.  Estudio de la expresion del transportador de glucosa GLUT-2 en el higado de pacientes diabéticos.  In  Fronteras Endocrinologia.  C. Dieguez, F.F. Casanueva (Eds.) Diaz Santos, Madrid, pp.19,1992.

105.     Sinha, M.K., C. Buchanan, C. Raineri-Maldonado, I.D. Goldfine and J.F.Caro.  Regulation of glucose transport by insulin and monoclonal insulin receptor antibodies in adipocytes of patients with NIDDM.  Adv Diabetologia  5:90,1992.

106.     Ravindra, R, J.F. Caro. Insulin stimulates GDP release from G proteins in the rat and human liver plasma. J Cell Biochem 53:181,1993.

107.     Arky, R.A., Caro, J.F., Johnson, C., Knowler, W.C., McManus, K., Moore, M.A., Sheps, S.G., Simonson, D.C. and Spratt, I.  Consensus Development Conference on the Treatment of Hypertension in Diabetes.  Diabetes Care. 16:1394,1993.

108.     Kolaczynski, J.W. and Caro, J.F.  Insulin-like Growth Factor-1 Therapy in Diabetes:  Physiological Basis, Clinical Benefits and Risks.  Ann Int Med 129:47,1994.

109.     Kolaczynski, J.W. and Caro, J.F.  Insulin-like Growth Factor-1 Therapy for Diabetes Mellitus?  Diabetes Care. 17:92,1994.

110.     Caro, J.F.  Insulin-Dependent Diabetes Mellitus in Adults.  In:  Current Therapy in Endocrinology and Metabolism, 5th Edition.  Bardin (Ed.) Mosby-Year Book, Inc. pp.384,1994.

111.     Burguera, B., Dudek, R.W., Caro, M., Slieker, L.J., Heath, W.F., Busby, J. and Caro J.F.  Upregulation of GLUT-2 protein levels in rat liver by chronic glucose administration.  Adv Diabetologia  7:23,1994.

112.     Kolaczynski, J.W., Morales, L.M., Moore, J.H., Considine, R.V., Pietrzkowski, Z., Noto, P.F. and Caro. J.F.  A new technique for biopsy of human abdominal fat under local anesthesia with lidocaine.  Acute and long term effects of lidocaine on human adipocytes in vitro revised. Int. J. Obesity  18:161,1994.

113.     Caro, J.F., M.S. Raju, M. Caro, C.J. Lynch, J.H. Exton, J.K. Thakkar, L. Roy, J.C. Hale, and W.J. Pories. Guanine nucleotide binding regulatory proteins in liver from humans with type II diabetes: evidence for altered "cross-talk" between the insulin receptor and Gi-proteins.  J Cell Biochem  54:309,1994.

114.     Long, S.D., O'Brien, K, McDonald, K.G., Frazier, N.L., Swanson, M.S., Pories, W.J., Caro, J.F.  Weight loss prevents the progression of impaired glucose tolerance to type II diabetes:  A longitudinal interventional study.  Diabetes Care  17:372,1994.

115.     Poulos, J.E., N. Leggett-Frazier, P. Khazanie, S. Long, R. Sportsman, K. MacDonald, and J.F. Caro. Circulating insulin-like growth factor concentrations in morbidly obese patients with NIDDM in response to the gastric bypass procedure. Horm. Met. Res. 26: 478,1994.

116.     Friedman, J.E., J.F. Caro, W.J. Pories, J.L. Azevedo, and G.L. Dohm. Glucose Metabolism in Incubated Human Muscle: effect of obesity and non-insulin dependent diabetes mellitus. Metabolism 8: 1042,1994.

117.     Burguera, B., C.W. Elton, J.F. Caro, E.B. Tapscott, W.J. Pories, R. DiMarchi, K. Sakano and G.L. Dohm.  Stimulation of glucose uptake by insulin-like growth factor II in human muscle is not mediated by the insulin-like growth factor II/mannose 6-phosphate receptor.  Biochem J 300:781,1994.

118.     Caro, J.F. and Rastogi, R.:  Diabetes.  In:  Talking Health with Dr. Brian McDonough.  B.P. McDonough (Ed.), Temple University Press, Philadelphia.  Chapter 5, pp.71,1994.

119.     Kennedy, J. and J.F. Caro.  Sex hormones and singers:  endocrine effects on voice.  J National Assoc Teachers of Singing.  November/December,1994.

120.     Caro, J.F., S. Triester, V.K. Patel, E.B. Tapscott, N.L.Frazier and G. L. Dohm. Liver glucokinase:  Decreased activity in patients with type II diabetes.  Horm Met Res.  27:18,1995.

121.     Poulos, J.E., T. Madigan, J. Serrano, J. Busby and J.F. Caro.  The effects of GTPγS on insulin binding to human liver plasma membranes.  Horm Met Res.  27:253,1995.

122.     Considine, R.V., M.R. Nyce, L.E. Allen, L.M. Morales, S. Triester, J. Colberg, S.L. Jacoby and J.F. Caro.  Protein Kinase C is Increased in the Liver of Humans and Rats with Non-Insulin-Dependent Diabetes Mellitus:  An Alteration not due to Hyperglycemia.  J Clin Invest.  95:2938,1995.

123.     Considine, R.V., E.L. Considine, C.J. Williams, M.R. Nyce, S.A. Magosin, T.L. Bauer, E.L. Rosato, J. Colberg and J.F. Caro.  Evidence Against Either a Premature Stop Codon or the Absence of Ob Gene mRNA in Human Obesity.  J Clin Invest.  95:2986,1995.

124.     Burguera, B., R.D. Dudek, and J.F. Caro. Liver GLUT-2 protein is not Upregulated in Non-Insulin Dependent Diabetes.  Horm. Met. Res.  27:341,1995.

125.     Hotamisligil, G.S., P. Arner, J.F. Caro, R.L. Atkinson and B.M. Spiegelman. Increased adipose tissue expression on TNF-α in human obesity and insulin resistance.  J. Clin. Invest.  95: 2409,1995.

126.     Moore, J.H., J.W. Kolaczynski, L.M. Morales, R.V. Considine, Z. Pietrzkowski., P.F. Noto and J.F. Caro.  Viability of Fat Obtained by Syringe Suction Lipectomy:  Effects of Local Anesthesia with Lidocaine.  Aesth Plast Surg.  19:335,1995.

127.     Caro, J.F.  Weight loss in severely obese subjects prevents type II diabetes and reveres insulin resistance and early type II diabetes.  Asia Pac. J. of Clin. Nut.  4:326,1995.

128.     Caro, J.F.  Biochemical Defects of Insulin Action in Humans.  In:  Diabetes Mellitus:  A Fundamental and Clinical Text..  Chapter 57.  Mosby-Year Book, Inc.,1995.

129.     Fair-Covely, R.M., and J.F. Caro.  Diabetes Mellitus.  In:  Current Diagnosis, 9th Ed.,1995.

130.     Sinha, M.K., J.P. Ohannesian, M.L. Heiman, A. Kriaciunas, T.W. Stephens and J.F. Caro.  Nocturnal rise of leptin in lean, obese and non-insulin dependent diabetes mellitus subjects. J. Clin. Invest.  97:1344,1995.

131.     Considine, R.V., M.K. Sinha, M.L. Heiman, A. Kriaciunas, T.W. Stephens, M.R. Nyce, J.P. Ohannesian, C.C. Marco, L.J. McKee,. T.L. Bauer and J.F. Caro. Serum Immunoreactive-Leptin concentrations in normal weight and obese humans.  New Engl J Med.  334:292,1996.

132.     Considine, R.V., M.R. Nyce, L.M. Morales, S.A. Magosin, M. Sinha, T.L. Bauer, E.L. Rosato, J. Colberg, and J.F. Caro.  Paracrine Stimulation of Preadipocyte Enriched Cultures Proliferation by Mature Adipocytes.  Am J Physiol. 270:E895,1996.

133.     Laine, C., and J.F. Caro. Preventing Complications in Diabetes Mellitus:  The Role of the Primary Care Physician. Medical Clinics of North America.  80:457,1996.

134.     Kennedy, J.W., and J.F. Caro.  The ABC’s of Hyperthyroidism in the older patient. Geriatrics.  51:22,1996.

135.     Kolaczynski, J., and J.F. Caro.  Molecular Mechanism of Insulin Resistance in Human Obesity.  Curr Opin. in Endocrinol. and Diabetes. 3:36,1996.

136.     Lynn, R.B., G.Y Cao, R.V. Considine, T.M. Hyde and J.F. Caro.  Autoradiographic localization of leptin binding in the choroid plexus of ob/ob and db/db mice.  Biochem. Biophys. Res. Comm. 219:884,1996.

137.     Hassink, S.G., E. DeLancey, D.V. Sheslow, J.F. Caro, R.V. Considine, J.W. Kolaczynski and A. Spitzer.  Serum leptin levels correlate with all indirect measure of adiposity in obese children.  Pediatrics. 98:201,1996.

138.     Kolaczynski, J.W., M.R. Nyce, R.V. Considine, G. Boden, J.J. Nolan, R. Henry, S.R. Mudaliar, J. Olefsky and JF. Caro.  Acute and Chronic Effect of Insulin on Leptin Production in Humans:  Studies in vivo and in vitro.  Diabetes. 45:699,1996.

139.     Considine, R.V., E.L. Considine, C.J. Williams, M.R. Nyce, P.L. Zhang, I. Opentanova, J.P. Ohannesian, J.W. Kolaczynski, T.L. Bauer, J.H. Moore and J.F. Caro.  Mutation screening and identification of a sequence variation in the human Ob gene coding.  Biochem. Biophys. Res. Comm. 220:735,1996.

140.     Hotamisligil, G.S., P. Arner, J.F. Caro, R.L. Atkinson and B.M. Spiegelman.  Differential regulation of adipose tissue TNF receptors in human obesity and insulin resistance.

140.Diabetes. 46:451,1996.

141.     Kolaczynski, J.W., R.V. Considine, J. Ohannesian, C. Marco, I. Opentanova, M.R. Nyce, M. Myint and J.F. Caro.  Responses of leptin to short-term fasting and refeeding in humans:  A link with ketogenesis but not ketones themselves. Diabetes 45:1511,1996.

142.     Considine, R.V., E.L. Considine, C.J. Williams, T.M. Hyde and J.F. Caro.  The Hypothalamic Leptin Receptor in Humans:  Identification of Incidental Sequence Polymorphisms and Absence of the db/db Mouse and fa/fa Rat Mutations.  Diabetes 19:992,1996.

143.     Laine, C. and J.F. Caro.  1996.  Subdiagnostico y deficiencia en el tratamiento de diabetes tipo 2.  MEDICO Interamericano 15:196,1996.

144.     Sinha, M.K., I. Opentanova, J. P. Ohannesian, M.L. Heiman, J. Hale, G.W. Becker, R.R. Bowsher, T.W. Stephens and J.F. Caro.  Evidence of Free and Bound Leptin in Human Circulation:  Physiological significance in lean and obese subjects and during short-term fasting.  J. Clin. Invest. 98:1277,1996.

145.     Nolan, J., J. Olefsky, M.R. Nyce, R.V. Considine and J.F. Caro.  Effect of Troglitazone on Leptin Production:  Studies in vitro and in human subjects.  Diabetes. 45:1276,1996.

146.     Hickey, M., R.V. Considine, R. Israel, M. McCammon, G. Tyndall, T. Mahar, J. Houmard and J.F. Caro.  Leptin is related to body fat content in male distance runners. Am. J. Physiol. 271:E938,1996.

147.     Caro, J.F., J.W. Kolaczynski, M.R. Nyce, J.P. Ohannesian, I. Opentanova, W.H. Goldman, R.B. Lynn, P.L. Zhang, M.K. Sinha, and R.V. Considine. Decreased CSF/Serum leptin ratio in human obesity:  A possible mechanism for "apparent" leptin resistance. Lancet. 348:159,1996.

148.     Caro, J.F., M.K. Sinha, J.W. Kolaczynski, P.L. Zhang, and R.V. Considine.  Leptin:  The Tale of an obesity gene. Diabetes 45:1455,1996

149.     Sinha, M.K., J. Sturis, J. Ohannesian, S. Magosin, T. Stephens, M.L. Heiman, K.S. Polonsky, and J.F. Caro. Ultradian Oscillations of Leptin Secretion in Humans. Biochem. Biophy. Res. Commun. 228:733,1996.

150.     Hickey, M. S., R. G. Israel, S. N. Gardiner, R. V. Considine, M. R. McCammon, G. L. Tyndall, J. A. Houmard, R. H. L. Marks, and J. F. Caro.  Gender Differences in Serum Leptin Levels in Humans.  Biochem. Mol. Med. 59:1,1996.

151.     Kolaczynski, J. W., and J. F. Caro.  Tolerance in Individuals with Diabetes. Chapter 10.  The Clinical Evaluation of a Food Additive, CRC Press,1996.

152.     Kolaczynski, J.W., J. P. Ohannesian, R. V. Considine, C. C. Marco, and J. F. Caro.  Response of Leptin to Short-Term and Prolonged Overfeeding in Humans. J. Clin. Endo. Metab. 81:4162,1996.

153.     Kennedy, J. W. and J. F. Caro.  The ABCs of Managing Hyperthyroidism in the Older Patient.   Geriatrics.  51:22,1996.

154.     Wing, R. R., M. K. Sinha, R. V. Considine, W. Lang and J. F. Caro.  Relationship between Weight Loss Maintenance and Changes in Serum Leptin Levels.  Horm. Metab. Res. 28:698,1996.

155.     Considine, R. V., and J. F. Caro.  Leptin: Genes, Concepts and Clinical Perspective.  Horm. Metab. Res. 46:249,1997.

156.     Considine, R. V., M. R. Nyce, J. W. Kolaczynski, P. Zhang, J. P. Ohannesian, J. H. Moore, Jr., J. W. Fox, and J. F. Caro.  Dexamethasone stimulates leptin release from human adipocytes: Unexpected inhibition by insulin.  J. Cell. Biochem. 65:254,1997.

157.     Hickey, M. S, J. A. Houmard, R. V. Considine, G. L. Tyndall, J. B. Midgette, K. E. Gavigan, L. Weidner, M. R. McCammon, R. G. Israel, and J. F. Caro.  Gender-dependent effects of exercise training on serum leptin levels in humans.  Am. Physiol. Soc. E562,1997.

158.     Caro, J.F. Leptin is Normal in PCOS, an Editorial about 3 “Negative” Papers.  J. Clin. Endo. & Metab. 82:1685,1997..

159.     Casanueva, F.F., C. Dieguez, V. Popovic, R. Peino, R. Considine, and J.F. Caro.  Serum immunoreactive-leptin concentrations in patients with anorexia nervosa before and after partial weight recovery. 1997. Biochem. and Mol. Med. 60:116,1997.

160.     Sreenan, Seamus, J. F. Caro, and S. Refetoff.  Thyroid Dysfunction is not Associated with Alterations in Serum Leptin Levels.  Thyroid. 7:407,1997.

161.     Considine, R. V. and .J. F. Caro.  Leptin and the Regulation of Body Weight. Int. J. Biochem. Cell Biol. 29:1255,1997.

162.     Hickey, M.S., J. A. Houmard, R. V. Considine, G. L. Tyndall, J. B. Midyette, K. E. Gavigan, M. L., Weidner, M. R. McCammon, R. G. Israel, and J. F. Caro. Exercise training improves insulin action but does not change serum leptin levels in obese humans.  Amer. J. Physiol. 59:1,1997.

163.     Sharma, K., R. Considine, B. Michael, S. Dunn, L. Weisberg, B. Kurnik, P. Kurnik, J. O’Connor, M. Sinha and J. F. Caro.  Plasma Leptin is Cleared by the Kidney and is Markedly Elevated in  emodialysis Patients.  Kidney Int. 51:1980,1997.

164.     Caro, J. F., Sinha, M. K., Kolaczynski, J. W., Zhang, P., Considine, R. V.  Leptin: The tale of an obesity gene.  Leptin as alternative treatment for human obesity.  BioMedicina,1997..

165.     Vidal-Puig, Antonio J., R. V. Considine, Mercedes Jimenez-Linan, Ariel Werman, Walter J. Pories, Jose F. Caro, and Jeffrey Flier.  Peroxisome Proliferator - activated receptor Gene Expression in Human Tissues Effects of Obesity, Weight Loss, and Regulation by Insulin and Glucocorticoids.  J. Clin. Invest. 99:2416,1997.

 166.     Schoeller, D. A., Cella, L. K., Sinha, M. K. , and Caro, J. F.  Entrainment of the Diurnal Rhythm of Plasma Leptin to Meal Timing.  J. Clin. Invest. 100:1882,1997.

167.     Wadden, T. A., R. V. Considine, G. D. Foster, D. A. Anderson, D. B. Sarwer, and J. F. Caro.  Short- and Long-Term Changes in Serum Leptin in Dieting Obese Women: Effects of Caloric Restriction and Weight Loss.  J. Clin. Endo. & Meta. 83:214,1998.

168.     Sinha, M. K. and J. F. Caro.  Clinical Aspects of Leptin.  Vitam. Horm. 54:1,1998

169.     Martin, L.J., .P.J.H. Jones, R.V. Considine, W. Su, N.F. Boyd and J.F. Caro.  Serum Leptin Levels and Energy Expenditure in Normal Weight Women.  Can. J. Physiol. Pharmacol. 76:237,1998.

170.     Stephens, T. W. and Caro, J. F.  To be Lean or not to be Lean, Is Leptin the Answer? Exp. Clin. Endocrinol. 106:1,1998.

171.     Caro, J.F. Leptin: From 1958 to the Present.  Can. J. Diab. Care. 22:518,1998

172.     Hickey, Matthew S., Pories, Walter J., Macdonald, Kenneth G., Cory, Kelly A., Dohm, G. Lynis, Swanson, Melvin S., Israel, Richard G., Considine, Robert V., Caro, Jose F., Houmard, Joseph A. A New Paradigm for Type 2 Diabetes Mellitus: Could it be a Disease of the Forgut?  Ann. Surg. 227:637,1998.

173.     Heini, AF, Lara-Castro, C, Kirk, KA, Considine, RV, Caro, JF, and RL Weinsier. Association of leptin and hunger-satiety ratings in obese women. Int. J. Obes. Relat. Metab. Disord. 22:1084,1998.

174.     Heiman, M. L., Chen, Yanyun, and Caro, J.F. Leptin participates in the regulation of glucocorticoid and growth hormone axes. J. Nutr. Biochem. 9:553,1998.

175.     Lage, M., R. V. Garcia-Mayor, M. A. Tome, F. Cordido, F. Valle-Inclan, R. V. Considine, J. F. Caro, C. Dieguez, F. F. Casanueva.  Serum leptin levels in women throughout pregnancy and the postpartum period and in women suffering spontaneous abortion. Clin.Endocrinol. 50:211,1999.

176.     Considine, R. V. and J. F. Caro.  Pleiotropic cellular effects of leptin. Curr Opin in Endocrinol and Diab. 6:163,1999.

177.     Heiman, M. L., Sloop, K. W., Chen, Y. and J. F. Caro.  Extension of Neuroendocrine Axes to Include Leptin.  J. Anim. Sci. 77:33,1999.

178.     Goldstein, D. J. and J. F. Caro.  Genetics and Potential Treatments for Obesity. The Management of Eating Disorders, Chapter 18. Humana Press, Inc., 1999.

179.     Ohannesian, J.P., Marco, C.C., Najm, P.S., Goldstein, B.J., Caro, J. F., and J.W. Kolaczynski.  Small Weight Gain is not Associated with Development of Insulin Resistance in Healthy, Physically Active Individuals. Horm. Metab. Res. 31:323, 1999.

179.

180.     Kolaczynski, J. W. and J. F. Caro.  Insulin Resistance: Site of the Primary Defect or How the Current and the Emerging Therapies Work. J. Basic & Clin. Physiol. & Pharmacol.281, 1999.

181.     Caro, J.F.  Obesity. In: McGraw-Hill. Yearbook of Science & Technology, 2000.

182.     Corominola, H., L.J. Conner, L.S. Beavers, R.A. Gadski, D. Johnson, J. Sluka, J.F. Caro and R. Rafaeloff-Phail.  Identification of Novel Genes Differentially Expressed in Omental Fat of Obese and Obese Type 2 Diabetic Patients. Diabetes 50:2822, 2001

183.     Caro, J. F. and M. Trautmann. Leptin: The Adipocyte Signal in the Control of Body Weight. In: Handbook of Experimental Pharmacology, 2000.

184.     Dananberg, J. and J.F. Caro.  Obesity.  In: Endocrinology. L.J. DeGroot, (Ed.), W. B. Saunders, 2000.

185.     Caro, J.F. and L.E. Stramm.  Biochemical Defects of Insulin Action in Humans.  In: Diabetes Mellitus. D. LeRoith, S.I. Taylor, and J.M. Olefsky, (Eds.), Lippincott-Ravin, 2000.

186.     Statnick, M.A., L.S. Beavers, L.J. Conner, H. Corominola, D. Johnson, C.D. Hammond, R. Rafaeloff-Phael, T.Seng, T.Suter, J.P. Sluka, E. Ravussin R.A. Gadski, and J.F. Caro. Decreased Expression of apM1 in Omental and Subcutaneous Adipose Tissue of Humans with Type 2 Diabetes. Int. J. Exp. Diabetes Res., 2000.

187.     Caro, J.F. and M.E. Trautmann.  Leptin: The Adipocyte Signal in the Control of Body Weight.  In: Obesity: Pathology and Therapy. T.G. Heffner and D.H. Lockwood, (Eds.), Springer-Verlag, 2000.

188.     Caro, J.F., R.V. Considine. Handbook of Obesity, Chapter 59. G. Bray and C. Bouchard (Eds), M. Decker and Co., 2001

189.     Rohner-Jeanrenaud, F., L. S. Craft, J. Bridwell, T. M. Suter, F. C. Tinsley, D. L. Smiley, D.R. Burkhart, M.A. Statnick, M.L. Heiman, E.R. Ravussin, and J.F. Caro.  Chronic central CART infusion decreases body weight and increases lipid oxidation in lean and high fat fed obese rats. Int J Obes Relat Metab Disord. Feb; 26(2):143-9,2002.

190.     Diabetes Prevention Program Research Group.  Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin.  New Engl J Med.  346:393,2002.

191.     Moyers, J.S. and Caro, J.F.  Insulin Resistance – Emerging Therapies for Affect Sites.In Insulin Resistance and Insulin Resistance Syndrome, Frontiers in Animal Diabetes, editedby B.C. Hansen and E. Shafrir.  pp 313-333, Taylor & Francis Publisher, NY 2003.

 192.     Caro, J.F.  Health Implication, Definitions and Classification of Obesity.  In: Endotext.com.  2004

 193.     Etgen, G.J., M.J. Prince, J.F. Caro.  Peroxisome Proliferator-Activated Receptor Modulators.   In: Diabetes Mellitu: A Fundamental and Clinical Text. D. LeRoith, S.I. Taylor, and J.M. Olefsky, (Eds.), Lippincott Williams & Wilkins, 2004..

194.     Caro, J.F., R.V. Considine. Handbook of Obesity, Chapter 59. G. Bray and C. Bouchard (Eds.), M. Decker and Co., 2004

195.     Caro, J.F. and Dananberg, J.  Obesity:  The Problem and its Management.  In: Endocrinology.  L.J. DeGroot, and J.L. Jameson (Ed). Elsevier, Saunders, 2005.

 196.   Serrano Rios, M. Caro, J. F., Carraro, C., Gutierrez Fuentes, J.A. Introduction In: The Metabolic Syndrome at      

           the Beginning of the XXI Century  A genetic and   MolecularApproach. ELSEVIER. 2006

 197.  Peer Support Programmes in Diabetes.  Advisor and Member of the Organization  Committee.  Report of

          WHO consultation, 5-7 November 2007. Publication WHO/CPM/08/01

 198    Caro, J.F.  On the Trail to Arrest the Progression of the Metabolic Syndrome. Endocrinol Nutr.  54 Supl 4: 37,    

       2007

 199    Caro, J.F., Rosas, J. Diabetes and Depression: Initial Questions. Journal of ALAD, 16: 50, 2008

 200    Considine, R. and Caro, J.F.   Obesity:  The Problem and its Management. In:    Endocrinology.  L.J. DeGroot,

           and J.L. Jameson (Ed). Elsevier, Saunders, 2010

 201    Caro, J.F. and Fisher E. Editorial. A Solution Might be Within People with Diabetes Themselves. Family

          Medicine, Supp 1: i1, 2010

 

 

 

 ABSTRACTS PRESENTED (incomplete list)

 

1.       Caro, J.F., A. Besarab, J.F. Burke, and J.A. Glennon. 1978. Propranolol: A possible role in the treatment of renal osteodystrophy. American College of Physicians Eastern Pennsylvania Regional Meeting.

2.          Caro, J.F., J.A. Glennon, and H.L. Israel. 1978. Neuroendocrine studies in sarcoidosis 8th International Congress of Sarcoidosis, Cardiff.

3.          Caro, J.F., and P.D. Woolf. 1979. Hyperprolactinemia diminishes pituitary LH reserve but no ovarian responsitivity to GnRH infusion. The Endocrine Society 61st Annual Meeting.

4.          Besarab, A., J.F. Caro, B.U. Ihle, and J.F. Burke. 1979. Beta-adrenergic blockade and hyperparathyroidism in chronic renal failure. Clin. Res., Eastern Section.

4.          Caro, J.F., and J.M. Amatruda. 1979. The effect of fasting on glucagon action and binding isolated rat hepatocytes. Clin. Res., Midwest Section.

5.          Caro, J.F., and J.M. Amatruda. 1980. Insulin-mimickers down regulate the insulin receptor: Evidence for a post receptor mechanism. Amer. Diab. Assoc., 40th Annual Meeting, Diabetes 29:38A.

6.          Caro, J.F., and J.M. Amatruda. 1980. Insulin receptor antibodies modulate insulin action and degradation independently of binding. The Endocrine Society 62nd Annual Meeting 

7.          Caro, J.F., J.M. Amatruda. 1980. Post receptor events regulate the insulin receptor. Amer. Diab. Assoc., 41st Annual Meeting, Diabetes 30:9A.

8.          Caro, J.F., G. Muller, and J.A. Glennon. 1982. Insulin processing by the liver. Amer. Diab. Assoc., 42nd Annual Meeting, Diabetes 31:133A.

9.          Kauffman, J.M., G. Muller, and J.F. Caro. 1982. Mechanism of insulin resistance in rat hepatocytes: a new model of chronic uremia. Amer. Diab. Assoc., 42nd Annual Meeting. Diabetes 31:124A.

10.       Caro, J.F., F. Cecchin, and M. Sinha. 1983. Is cell glycosylation needed for insulin binding and post binding events? Amer. Diab. Assoc., 43rd Annual Meeting. Diabetes 32:32A.

11.       Caro, J.F., and S. Lanza-Jacoby. 1983. Insulin resistance in uremia: the role of the liver. The Endocrine Society, 65th Annual Meeting.

12.       Caro, J.F., F. Cecchin, F. Folli, and M. Sinha. 1983. Triiodothyronine-induced insulin resistance in primary cultures of rat hepatocytes. European Thyroid Association, XII Annual Meeting. Annales, d endocrinology, 44:87A.

13.       Caro., J.F., F. Folli, M. Sinha, and D. Brancaccio. 1984. Insulin resistance in uremia: in vitro model to study mechanism(s) in the liver. Amer. Diab. Assoc. 44th Annual Meeting. Diabetes 38:138A.

14.       Sinha, M.K., and J.F. Caro. 1984. Insulin mediator in serum? Recognition of an artifact. Amer. Diab. Assoc. 44th Annual Meeting. Diabetes 38:140A.

15.       Caro, J.F., O. Ittoop, and M.K. Sinha. 1984. Tolazamide and glyburide but not ciglytazone enhance insulin action in the liver. 7th International Congress of Endocrinology 

16.       Caro, J.F., M.K. Sinha, M.L. McCaleb, G.B. Wish, and D.H. Lockwood. 1985. Insulin resistance in uremia is due to a post insulin receptor kinase defect(s). Clin. Res. 33:426A.

17.       Sinha, M.K., O.Ittoop, and J.F. Caro. 1985. Enhanced insulin receptor kinase activity in a patient with extreme insulin resistance and acanthosis nigricans. Clin. Res. 33:444A.

18.       Caro, J.F., O. Ittoop, W. Pories, R. Dudek, and M.K. Sinha. 1985. Insulin responsive human hepatocytes. Amer. Diab. Assoc. 45th Annual Meeting. Diabetes 34:50A.

19.       Sinha, M.K., O. Ittoop, M. Jenquin, and J.F. Caro. 1985. Effect of down-regulation and tunicamycin on insulin receptor autophosphorylation and kinase activity. Amer. Diab. Assoc. 95th Annual Meeting. Diabetes 34:159A.

20.       Dohm, G.L., J.F. Caro, and M.K. Sinha. 1985. Insulin receptors and insulin receptor protein kinase activity in muscle of endurance trained rats. Medicine and Science in Sport and Exercise 17:240.

21.       Caro, J.F., F. Cecchin, F. Kasperek, M. Jenquin, O. Ittoop, and M.K. Sinha. 1985. Insulin resistance in uremia: insulin receptor kinase activity in liver and muscle is different. XII Congress of the International Diabetes Foundation.

22.       Caro, J.F., G.L. Dohm, and M.K. Sinha. 1985. Insulin resistance in uremia: decreased hepatic fructose 2,6-bisphosphate. XXI Congress of the International Diabetes Federation.

23.       Caro, J.F., W. Pories, O. Ittoop, M. Jenquin, H.D. Meelheim, E. Flickinger, J.F. Silverman, F. Thomas, M.K. Sinha. 1985. Mechanism of insulin resistance in isolated hepatocytes from morbidly obese patients with NIDDM. Int. J. of Obesity 9:A15.

24.       Sinha, M.K., W. Pories, M. Jenquin, O. Ittoop, H.D. Meelheim, E. Flickinger, J.F. Caro. 1985. Down regulation of insulin receptors and insulin action in cultured adipocytes from morbidly obese patients with or without NIDDM. Int. J. of Obesity 9:A95.

25.       Caro, J.F., M.K. Sinha, and I.D. Goldfine. 1986. Monoclonal antibodies to the human insulin receptor that activate glucose transport but not insulin receptor kinase activity. III International Symposium on Insulin Receptors and Insulin Action. Madrid, Spain.

26.       Caro, J.F., O. Ittoop, W. Pories, D. Meelheim, and M.K. Sinha. 1986. Studies on the mechanism of insulin resistance in the liver from humans with Noninsulin-dependent Diabetes: insulin action and binding in isolated hepatocytes, insulin receptor structure and kinase activity.  III International Symposium on Insulin Receptors and Insulin Action. Madrid, Spain 

27.       Dvornik, D., R. Gonzales, D. Hicks, T. Smith, S. Ryder, J.F. Mullane, P. Raskin, J. Rosenstock, P. Challis, J. Caro, and W. Fore. 1985. Effect of tolrestat on RBC sorbitol levels in subjects with diabetes mellitus. Diabetes Research and Clinical Practice. Supplement I:S146.

28.       Silverman, J.F., D.J. Dabbs, K.F. O'Brien, H.T. Norris, and J. Caro. 1987. Liver pathology in morbid obesity. Laboratory Investigation. 56:IA.

29.       Pories, W.J., J.F. Caro, E.G. Flickinger, H.D. Meelheim, and M.S. Swanson. 1987. The control of diabetes mellitus (NIDDM) in the morbidly obese with the Greenville gastric bypass operation. 107th Meeting of the American Surgical Association.

30.       Caro, J.F., S.I. Taylor, O. Ittoop, S.M. Raju, and W.J. Pories. 1987. Endogenous substrates of insulin receptor kinase in human liver plasma membranes: defect(s) in NIDDM. The Endocrine Society.

31.       Sinha, M.K., W.J. Pories, E. Flickinger, D. Meelheim, S. Atkinson, N.S. Sehgal, and J.F. Caro. 1987. Insulin worsens the insulin resistance of adipocytes in primary culture from obese and NIDDM subjects. The 69th Annual Meeting of the Endocrine Society, Indianapolis.

32.       Caro, J.F., M.K. Sinha, S.M. Raju, O. Ittoop, W.J. Pories, D. Meelheim, E. Flickinger, and G.L. Dohm. 1987. Insulin receptors and insulin receptor kinase activity in human skeletal muscle from obese subjects with and without NIDDM. American Diabetes Association, 47th Scientific Sessions Meeting, Indianapolis 

33.       Forsayeth, J.R., J.F. Caro, M.K. Sinha, B.A. Maddux, and I.D. Goldfine. 1987. Monoclonal antibodies to the human insulin receptor activate glucose transport but not insulin receptor kinase activity. Clinical Research 35:622A.

34.       Caro, J.F., S.M. Raju, M.K. Sinha, I.D., Goldfine, and G.L. Dohm. 1988. Heterogeneity of human liver, muscle, and adipose tissue insulin. Clinical Research 36:479A.

35.       Caro, J.F., A. Rovira, J.J. Chen, N. Leggett, K. O'Brien, C. Sash, K. Parker, F. Thomas, and G. L. Dohm. 1988. Insulin resistance in the skeletal muscle of uremic patients is a post insulin receptor kinase defect(s). Clinical Research 36:479A.

36.       Caro, J.F., J. Poulos, O. Ittoop, N. Mooney, and M.K. Sinha. 1988. Insulin-like growth factor I receptors in hepatocytes from human liver, human hepatoma and normal, regenerating and fetal rat liver. Clinical Research 36:479A.

37.       Dohm, G.L., C.W. Elton, W. J. Pories, E.C. Flickinger, S.M. Atkinson, and J.F. Caro. 1988. Changes in glucose transport and insulin sensitivity of in vitro incubated human muscle from obese and diabetic subjects. The FASEB Journal, Vol. 2, No. 5.

38.       Sinha, M.K., C. Buchanan, L. Martin, R. DiMarchi, and J.F. Caro. 1988. Insight into the mechanism of 16F-1 stimulated glucose transport in human fat cells. The Endocrinology Society Program and Abstracts, 70th Annual Meeting, 517.

39.       Chen, J.J., N. Leggett, W. Pories, E. Flickinger, K. O'Brien, P. Khazanie, and J.F. Caro. 1988. Noninsulin dependent diabetes mellitus worsens the severe insulin resistance of morbid obesity. The Endocrinology Society Program and Abstracts, 70th Annual Meeting, 1105.

40.       Thakkar, J.K., R. DiMarchi, and J.F. Caro. 1988. Insulin, IGF-I and IGF-II do not stimulate phosphatidylinositol-4, 5-biphosphate specific-phospholipase C in human liver. Diabetes Program 48th Annual Meeting, 114.

41.       Sinha, M.K., C. Buchanan, L. Martin, R. DiMarchi, and J.F. Caro. 1988. Presence of IGF-II receptors and IGF-II stimulation of glucose metabolism in human adipocytes. Diabetes Program 48th Annual Meeting, 729.

42.       O'Brien, K.F., T.C. Chen, T.C. Chenier, and J.F. Caro. 1988. Using oral glucose tolerance test to evaluate glucose uptake, insulin release, and resistance.  Eastern North American Regional Biometrics Society, Boston, Massachusetts.

43.       Pories, W.J., E.G. Flickenger, K.G. MacDonald, and J.F. Caro. October 1989. Long Term effect of the gastric bypass operation on weight, diabetes, hypertension, and mental health in the morbidly obese.  Clinical Congress, American College of Surgeons, Atlanta, Georgia.

44.       Thomas, F., W. Costellani, C. Sash, H. Daniel, L. Dabuey, P. Cunningham, A. Ferguson, and J.F. Caro. 1989. Studies of radioimmunescence reactive urinary insulin in humans. New Test for Diagnosis of Pancreas Rejection. First International Congress of Pancreatic and Islet Transplanting. Diabetes 38(Sup 1):253 

45.       Dunham, D., S. Marcuard, A. Hobbs, and J.F. Caro. 1989. Availability of insulin from total parenteral nutrition (TPN) solutions. 13th Clinical Congress Abstracts. JPEN 13(Supp)1:8S.

46.       Caro, J.F., M.K. Sinha, and G.L. Dohm. Insulin Resistance. 1989. J. Cell Biochemistry (Supp 13E):224 

47.       Dohm, G.L., C.W. Elton, S.M. Raju, N. Mooney, R. Dimarchi, W.J. Pories, E.G. Flickinger, S.M. Atkinson, and J.F. Caro. 1989. IGF-I and IGF-II stimulated glucose transport in human skeletal muscle: IGF resistance in obesity and NIDDM. Diabetes, 49th Annual Meeting, 50A.

48.       Sinha, M.K., C. Buchanan, C. Raineri-Maldonado, P. Khazanie, W.J. Pories, R. Dimarchi and J.F. Caro. IGF-I Stimulated glucose transport, IGF-I receptors and tyrosine kinase are not altered as noted for insulin in adipocytes from NIDDM patients. Diabetes, 49th Annual Meeting, 103A.

49.       Elton, C.W., E.B. Tapscott, J.F. Caro, P.F. Pilch, W.J. Pories, S.M. Atkinson, and G.L. Dohm. 1989. "Effect of moderate obesity on glucose transport in human muscle." Int. J. Obes., 1989 Annual Meeting of the North American Association for the Socity of Obesity.

50.       Caro, J.F., S.M. Raju, N. Leggett-Frazier, L. Roy, S. Long, and K. O'Brien. 1990. "Altered coupling of the insulin receptor with Gi protein in the liver from patients with NIDDM." ADA 50th Annual Meeting and Scientific Sessions.

51.       Caro, J.F., M.K. Sinha and G.L. Dohm. Insulin resistance in obesity. 1990. Int. J. Obes. (Supp) 2:28.

52.       Caro, J.F., M.K. Sinha, G.L. Dohm. July 1990. Alterations in insulin receptors and glucose transporters in obese and diabetic man.  Fundamental and Clinical Pharmacology 4 (Supp)1:10S.  Pathophysiology and Treatment of Diabetes Melllitus (Satellite Meeting of the Amsterdam XIth International Congress of Pharmacology), Montpellier, France 

53.       Marcuard, S.P., B. Dunham, M.K. Sinha, S.J. Raju, J.F. Caro., May 1991.  Insulin binds to heparinin TPN solutions.  American Gastroenterological Association, New Orleans, Louisiana.

54.       Caro, J.F., M.K. Sinha, W.J. Pories, H.A. Barakat, P.G. Khazanie, G.L. Dohm.  1991.  J Cell Bioch. (Supp. 15B):13, CA023.

55.       Burguera B., R.K. Stanzak, L.J. Slieker, W.F. Health, N. Leggett-Frazier, L. Roy, S. Long, and J.F. Caro. 1991. Is the low level of GLUT-2 gene expression present in impaired glucose tolerant patients (IGT) preventing or inducing non-insulin dependent diabetes mellitus (NIDDM)? 73rd Annual Meeting, The Endocrine Society, #1765, pg. 472

56.       Friedman, J.E., W.J. Pories, N. Leggett-Frazier, L.L. Roy, S.D. Long, J.F. Caro, and G.L Dohm. 1991. Evidence for decreased insulin sensitive glucose transporters (GLUT 4) in skeletal muscle for a large sample of obese and obese-NIDDM patients. ADA 51st Annual Meeting and Scientific Sessions. Diabetes #630.

57.       Sinha, M.K., T. Madigan, G. Cooper, and J.F. Caro. 1991. Effect of amylin and calcitonin gene related peptide-1 (CGRP-1) on glucose transport in isolated adipocytes from lean, obese and NIDDM patients. ADA 51st Annual Meeting and Scientific Sessions. Diabetes #955, pg. 239A 

58.       Barakat, H.A., K. O'Brien, S. Long, P. Khazanie, W. Pories, and J. Caro. 1991. Coronary artery disease risk factors in morbidly obese women with normal glucose tolerance. ADA 51st Annual Meeting and Scientific Sessions. Diabetes #1711, pg. 429A.

59.       MacDonald, K.G., W.J. Pories, C.A. Moore, N. Leggett-Frazier, C. Jone, S. Long, E. Morgan, L. Roy, J.F. Caro. 1992. The reversal of diabetes mellitus (DM) with gastric bypass: correlation of duration of diabetes with glucose response and insulin release. Annual Meeting, American Society for Bariatric Surgery, New Orleans.

60.       Ravindra, R., J.F. Caro. 1992. Insulin stimulates GDP release from G proteins in the rat and human liver.  74th Annual Meeting, The Endocrine Society, Texas, #23, pg. 57.

61.       Long, S.D., K. O'Brien, M. Swanson, K. MacDonald, N. Frazier, W.J. Pories, J.F.Caro. 1992. Weight loss prevents the progression of impaired glucose tolerance to non-insulin dependent diabetes mellitus: A ten year longitudinal study. 52nd Annual Meeting, Diabetes #266. pg. 72A 

62.       Ravindra, R. and Caro, J. 1993.  Effect of Glucagon on GDP release from G Proteins in the rat liver plasma membranes.  75th Annual Meeting, The Endocrine Society #526. pg. 182.

63.       Moore, J.H., Kolaczynski, J.W., Morales, L.M., Considine, R.V., Pietrzkowski, Z., Noto, P.F. and Caro, J.F.  1993. Viability of fat obtained by syringe suction lipectomy:  Effects of local anesthesia with Lidocaine.  The Lipoplasty Society of North America, Inc., Annual Meeting, New Orleans 

64.       Considine, R.V., Allen, L., Nyce, M., Noto, P., Triester, S., Morales, L.M. and Caro, J.F. 1994.  Membrane protein kinase C is increased in NIDDM liver.  Studies of PKC isozyme distribution in both humans and a rat model.  54th Annual Meeting, American Diabetes Association, New Orleans.

65.       Swanson, S., Long, E., Smith, K., MacDonald, G., Dohm, N., Frazier, J. Caro, J and Pories W.  1994.  Early gastric bypass provides better control of NIDDM in the morbidly obese.  7th ICO Satellite Symposium, Surgical Treatment of Obesity, Montreal, Quebec

66.       Koda, J.E., Fineman, M.S., O.G. Kolterman, and Caro, J.F.  1995.  24 Hour Plasma Amylin Profiles are Elevated in IGT Subjects vs. Normal Controls.  55th Annual Meeting and Scientific Sessions American Diabetes Association, Atlanta, Georgia, Diabetes #876, pg. 45A.

67.       Spiegelman, B.M., P. Arner, J.F. Caro, R.L. Atkinson and G.S. Hotamisligil.  1995.  Elevation of Adipose Tissue Expression of TNFα and TNF Receptors in Human Obesity and Insulin Resistance. 55th Annual Meeting and Scientific Sessions American Diabetes Association, Attanta, Georgia, Diabetes #164, pg. 45A.

68.       Considine, R.V., E.L. Considine, C.J. Williams, M. Nyce, S.A. Magosin, T.L. Bauer, E.L. Rosato, J. Colberg and J.F. Caro.  1995.  Ob Gene Expression is Increased in Adipocytes from Obese Humans.  55th Annual Meeting and Scientific Sessions, Atlanta, Georgia, Diabetes #739, pg. 202A..

69.       Heini, A.F., R.V. Considine, J.F. Caro, H. Schneider, and R.L. Weinsier.  1996.  The Effect of a Hydrolyzed Guar Fiber on Fasting and Postprandial Glucose Metabolism, Cholecystokinin, Leptin and Satiety.  XVIII ESPEN Congress, Geneva, Switzerland.

70.       Heini, A.F., C. Lara-Castro, R.V. Considine, J.F. Caro, and R. L. Weinsier. 1996. Leptin and Satiety in obese women. XVIII ESPEN Congress, Geneva, Switzerland

71.       Schoeller, D.A., Cella, L. Kessler, Sinha, M., and Caro, J.F. 1996.  Entrainment of the Diurnal Variation in Plasma Leptin Levels.  North American Association for the Study of Obesity.Breckenridge, Colorado

72.       Israel, R.G., M.S. Hickey, R.V. Considine, T.L. Mahar, M.R. McCammmon, G.L. Tyndall, J.A. Houmard, and J. F. Caro.  1996. Leptin is Related to Fat Mass in Highly Trained Endurance Runners.  North American Association for the Study of Obesity. Breckendridge, Colorado

73.       Wauters, M., R. Considine, C. Van Broeckhoven, I. De Leeuw, J. Caro, L. Van Gaal.  1996.  Associations of Leptin with Body Composition are Influenced by Apoe Polymorphism in NIDDM Patients.  North American Association for the Study of Obesity. Breckenridge, Colorado

74.       Letiexhe, M.R., A. J. Scheen, J.F. Caro and P.J. Lefebvre.  1997.  Post-Gastroplasty Recovery of Ideal Body Weight Normalizes Serum Leptin Levels of Obese Women.  Diabetologia. 40:A263.

75.       Letiexhe, M.R., A.J. Scheen, F. Sodoyez-Goffaux, J.F. Caro and P.J. Lefebvre.  1997.  Relationships between Basal Plasma Leptin, Fasting Total or True Insulin Levels, and Insulin Sensitivity Index S1 in Lean, Oese and Post-Obese Females.  International Journal of Obesity. 21:(Suppl.2). S101

76.       Zhang, P.L., J.D. Liang, G.E. Sandusky, B. Burguera, R,V. Considine, T.M. Hyde, H.M. Hsiung, P.R. Sankhavaran, M.A. Esterman, E. Maratos-Flier and J.F. Caro.  1998.  Hypothalamic MCH mRNA and Protein are Increased in Human Obesity.  Genetic and Molecular Basis of Obesity, Satellite Symposium of the 8th International Congress on Obesity.  Paris, France.

77.       Statnick, M.A., P.L. Zhang, C. Hammond, L. Beavers, L.J. Conner, D. Johnson, T.M. Suter, R. Gadski and J.F. Caro,  1998.  Expression of SOCS3, An Inhibitor of Leptin Signaling, is not Altered in the  anterior Hypothalamus of Obese Humans.  Genetic and Molecular Basis of Obesity, Satellite Symposium of the 8th International Congress on Obesity.  Paris, France.

78.       Woodworth, J.R., D.C. Howey, R.R. Bowsher, M.E. Trautmann and J.F. Caro.       1998.  The Pharmacokinetics and Acute Effects of LY355101, a Novel Anti-obesity Protein, in Healthy Volunteers. Genetics and Molecular Basis of Obesity, Satellite Symposium


 

Patents

 

 

1.-Pulsatile delivery of leptin receptor ligands

United States 08/804,668

 

2.-Modulation of the hypothalamic-pituitary-adrenal-adipose axis with leptin receptor ligands

Europe EP 0991420 A1

 

3.-Treatment of infertility with leptin receptor ligands

Europe EP 0991419 A1

 

4.-Prevention of muscle mass loss with leptin receptor ligands

Europe EP 1128840 A1

 

5.-Isolated Stromal Cell and Methods of Using the Same

United States 20120213752

 

6.-Implant Compromising immunologically isolated stroma cell and its use

Europe EP1304112


 

title

Click to add text, images, and other content

title

Click to add text, images, and other content